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Abstract 
To overcome obesity, new approaches to control energy intake are required. Dietary 
macronutrient composition is one key determinant of energy intake in various species including 
mammals and humans (Gosby et al., 2011; Huang et al., 2013; Simpson & Raubenheimer, 
2005; Solon-Biet et al., 2014; Sorensen et al., 2008). Protein, in particular, is an important 
suppressor of appetite followed by carbohydrate and then lipid (Westerterp-Plantenga et al., 
2009). However, how different proteins modulate appetite differentially and the mechanisms 
that underlie these differences are not well understood. In the mouse studies described in this 
thesis, I compared the intakes of two different protein sources, casein and whey at different 
levels of %P on energy intake and endeavoured to correlate the differences observed with 
differences in the plasma levels of appetite modulating hormones.   
 
Study 1:  
A food preference study conducted on age-matched 16 male C57BL/6J mice caged in pairs 
that had ad libitum access to two different diets that contained identical %P but differed in their 
protein sources. Bovine milk casein and whey were used as the two protein sources in high 
energy (17 MJ/kg) diets, in which %C fixed, and %F was allowed to change as %P changed.  
To identify differences between the two protein sources %P was varied in the following 
sequence 23%P, 13%P, 33%P, 10%P and 7.5%P. Chow used as a control. Mice were allowed 
to choose between either casein or whey. At high %P (23 or 33), the mice preferred casein to 
whey. At 23%P, for example, the casein: whey preference was 85.1 ± 2.3%: 14.9 ± 2.3 %. As 
%P fell an interesting shift in food preference occurred from casein to whey. Thus, at ten %P, 
the casein: whey preference was 37.2 ± 2.7%: 62.8 ± 2.7%. 
xx 
 
Interestingly, there was no significant difference in total food intake between 10%P-33%P, 
demonstrating that the mice were able to maintain energy intake while re-balancing their 
intakes of different amino acids. From 8 amino acids that relatively enriched in whey compared 
to casein, we identified three amino acids, L-Cys, L-Thr and L-Trp whose intakes were 
relatively stable as the food preference shifted from casein to whey as %P fell from its control 
level of 23%P to low 10%P are potent to regulate appetite and preference shift.      
 
Study 2: 
This study was conducted to confirm that the preference shifts that observed in Study 1 to fix 
%C did not depend on the decision. For this reason I repeated the  food preference study on 24 
male  C57BL/6J mice, divided into two groups under two distinct conditions in which either 
(1) carbohydrate content was held constant at 50% of total energy (as in the study described in 
Chapter 3) or (2) fat was held constant at 27% of total energy. For the 23%P control diet, %C 
was 50 and %F was 27%. The outcomes of study 2 closely resembled those of Study 1. Also, 
I observed that the protein content of the diets modulated the fasting plasm level of the peptide 
hormone FGF-21.   
 
Study 3:  
I studied the impact of the three candidate amino acids L-Cys, L-Thr and L-Trp as dietary 
supplements on food intake, focusing on low %P (10) and the casein diet. In particular, I 
hypothesised that one or more of these amino acids might suppress food intake under these 
circumstances to the level observed for 10%P whey and 23%P whey or casein. C57BL/6J mice 
in 6 groups of eight were caged in pairs and studied for ten weeks. After an initial chow diet 
treatment, groups 2-6 were provided with a 23%P casein diet (%F fixed), and group 1 provided 
with   23%P whey diet.  Subsequently, all groups were transferred to 10%P diets for four weeks. 
xxi 
 
Group 1 remained on whey; group 2 remain on casein and groups 3-5 were assigned to casein 
supplemented with one of L-Cys or L-Thr or L-Trp at the levels found in 23%P whey.  Group 
6 assigned to casein supplemented with a combination of L-Cys, L-Thr L-Trp to test whether 
there might be an enhanced effect on food intake or the plasma levels of appetite modulating 
hormones. I observed that supplementation of casein with L-Cys suppressed food intake to a 
level comparable to that observed for 10%P whey or 23%P whey or casein. Also, I observed 
that L-Cys suppressed the fasting plasma level of FGF-21. The results are consistent with the 
hypothesis that L-Cys is a limiting amino acid as %P falls in only casein-based diets but not 
whey-based diets and that dysregulation of FGF-21 results in enhancing plasma FGF-21 level 
and increase protein appetite and total food intake. Selective supplementation of casein with 
L-Cys but not two others amino acids L-Thr and L-Trp or access to an L-Cys rich protein 
source, whey overcomes the excess intake of energy how %P diets exposed relative 
deficiencies of amino acids including conditionally essential amino acids such as L-Cys and 
require further study as a potential explanation for inappropriate total energy intake and 
attendant overweight and obesity.   
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General introduction 
1.1 Obesity a global problem 
Obesity is a health problem which is characterised as deposition of excessive fat mass. This is 
a common phenomenon when chronic energy intake consistently exceeds energy expenditure 
and excess energy deposit in the white adipose tissue (Lam & Ravussin, 2016). Obesity and 
obesity-related diseases have become a global health epidemic. According to the World Health 
Organization, in 2016, more than 1.9 billion adults were overweight and among those over 650 
million were obese, whereas over 340 million children and adolescents aged 5-19 were 
overweight or obese (Ng et al., 2014; WHO, 2016). During the 33 years from 1980 to 2013, 
overweight and obesity combined rose by 27.5% for adults and 47.1% for children (Ng et al., 
2014).  
Obesity is the major risk factor for numerous chronic diseases, including diabetes, 
cardiovascular disease, certain cancers, osteoarthritis and chronic kidney disease (Ng et al., 
2014). The prevalence of such disease has been increasing in line with obesity. During 2005 to 
2015 global deaths from cardiovascular disease increased 12.5%, ischaemic heart disease 
increased by 16.6%, diabetes increased by 32.1%, and chronic kidney disease increased by 
31.7% (Wang H, 2016). 
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1.2 Causes of obesity 
 
The major drivers of the obesity epidemic much debated (Swinburn, Sacks & Ravussin, 2009). 
Among several, interconnected potential contributors are changes in the composition of the 
diet, decreasing levels of physical activity and changes in the gut microbiome (Astrup & Brand-
Miller, 2012; Bleich et al., 2008; Drewnowski & Popkin, 1997; Lim et al., 2012; Prentice & 
Jebb, 2004; Swinburn, 2013; Swinburn, Sacks & Ravussin, 2009; Tilg & Kaser, 2011; 
Turnbaugh et al., 2009; Turnbaugh et al., 2006). Increased total energy intake rather than 
reduced energy expenditure is widely accepted to be the primary driver of obesity (Swinburn 
et al., 2009), but why this has occurred remains incompletely understood.  
 
1.3 Protein Leverage Hypothesis 
The composition of protein, fat and carbohydrate in the diet can influence food intake. For 
decades the main focus of research into the causes of excess energy intake was focused on 
carbohydrate and lipid content in the diet. Protein has been largely ignored as a causative factor 
for obesity, in total dietary energy intake protein contributes small part compared to 
carbohydrate and lipid, and during last few decades, protein intake remains consistent in the 
era of the development obesity epidemic (Simpson & Raubenheimer, 2005). However, studies 
have suggested that the ratio of protein to non-protein energy in the diet may provide a much 
stronger predictor of total energy intake (Gosby et al., 2014; Huang et al., 2013; Simpson & 
Raubenheimer, 2005; Solon-Biet et al., 2014; Sorensen et al., 2008).     
 
Some studies on animal including insects, birds, fish and mammals had identified that animals 
have separate appetites for protein, carbohydrate and fat (Berthoud & R., 2000; Raubenheimer 
3 
 
& Simpson, 1997). Simpson and Raubenheimer proposed that predominant protein appetite 
may play a key role in the human obesity epidemic- the protein leverage hypothesis (PLH) 
(Simpson & Raubenheimer, 2005). Although the Protein Leverage Effect is well established 
for vertebrates and insects (Berthoud et al., 2012; Raubenheimer & Simpson, 1997), but in 
human it is controversial (Martens, Lemmens & Westerterp-Plantenga, 2013). A recent review 
paper (Raubenheimer & Simpson, 2019) and randomised controlled study justify PLE in 
human (Gosby et al., 2011). In a human study trial, it was observed that decreasing amount of 
protein in the diet from 15% to 10% increased food intake 12% but did not change total energy 
intake when per cent dietary protein increased from 15% to 25% (Gosby et al., 2011). Evidence 
for the Protein Leverage Effect (PLE) from various human and animal studies provided in 
Table 1.1. 
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Table 1.1 Studies providing evidence in support of the protein leverage hypothesis of energy intake 
Author & Year Title Subjects Research Design Response 
Huang et al., 2013, 
Obesity 21, 85-92 
(Huang et al., 2013) 
Effect of dietary 
protein to 
carbohydrate balance 
on energy intake, fat 
storage and heat 
production 
- Nine weeks old, 
50 male 
C57BL6/J mice 
(16-week study) 
- 25 weeks old, 
229 male 
C57BL6/J mice 
for thermogenesis 
 
- Mice had ad libitum access to 
one of 5 isoenergetic diets 
varied in protein and 
carbohydrate. 
- Mice had ad libitum access to 
one of the 25 diets varied in 
protein, carbohydrate and lipid 
- Energy intake was negatively correlated with 
dietary protein content. 
- Food intake ­ when P:C ratio ¯  and vice-versa.  
- Mice near balance diet (P:C = 23: 57) had greatest 
­body mass and high P:C (48:33) had ¯ weight 
gain 
- Mice on the lowest P:C ratio had the greatest 
depots of visceral fat pads 
- Three key regulators of thermogenesis (UCP1, 
DIO2 and PGC1a) ­ in mice fed highest P:C diet 
and ¯ in mice fed lowest (P:C)  
Solon-Biet et al., 
2014, Cell 
Metabolism 19, 
418-430 (Solon-
Biet et al., 2014) 
The Ratio of 
Macronutrients, not 
caloric intake dictates 
cardiometabolic 
health, aging and 
longevity in ad 
libitum-fed mice 
- Three weeks old 
Male and female 
C57BL/6J mice 
- Eight weeks old 
male C57BL/6J 
mice for acute 
study 
 
- Total 858 mice, ad libitum 
access to one of 25 diets 
varied in protein (5% - 60%), 
carbohydrate (16%-75%), fat 
(16% - 75%) and energy (8,13 
and 17 kJ g-1) density. 
- Culled 183 mice across diet 
treatment after 15 months 
- ­ food intake as the concentration of % P or % C ¯  
- % F had a negligible influence on food intake  
- Leptin positively associated with body fat and total 
macronutrient intake  
- Mice between 6 to 15 months ate a similar amount 
of protein regardless of energy density. 
- Lifespan was greatest with low %P and high %C  
- Protein intake for low energy and high energy was 
similar (except old mice) 
Note: ­ refers to increase or high or up, ¯ refers to decrease or low or down         (Continue) 
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Author & Year Title Subjects Research Design Response 
Sørensen et.al., 
2008, Obesity,16 
566-571 (Sorensen 
et al., 2008) 
Protein-leverage in 
Mice: The 
Geometry of 
Macronutrient 
Balancing and 
Consequences for 
Fat Deposition 
- Five weeks old 152 
Outbred male mice of 
NMRI strain 
 
Experiment 1: 
- Seventy-five mice divided 
into five diet groups, 15 mice 
per group. Mice housed 
individually, given ad 
libitum access to 5 different 
diets varied in %P and %C 
but %F fixed  
Experiment 2: 
Sixty mice, four diet group, 
housed singly. The choice 
between two diets varied in 
%P and %C 
Experiment 1: 
- ­ food intake/ energy intake with  ¯ % P in the diet 
- Fat storage ­ with ¯ % P diet because food 
intake­.    
Experiment 2: 
- First 3 weeks of diet treatment food intake was 
inconsistent in the choice.  
- After 3weeks mice had preferred low %P diet 
over high %P diet 
-  Mice regulated P intake target strongly over C  
  
Gosby et al. 
2011, PLOS ONE, 
6 (11) 
(Gosby et al., 
2011) 
 
Testing protein 
leverage in lean 
human: A 
randomised 
controlled 
experimental study 
 Human, 
lean and healthy six 
male and 16 females, 
(BMI = 18-25 kg m-2) 
- Three 4-day periods in house 
dietary study, the single-sex 
group at a time 
- Each 4-day ad libitum access 
to 10%, 15% or 25% protein 
- Participants were blinded to 
the treatment 
1 hour supervised walk each 
day 
- 12% ­ Food intake over four days on a 10% P diet 
compare to15% P diet 
- ­ 57% in total energy intake from  ­ savoury food 
and 43% sweet foods 
- ­ %P in the diet to 25%P did not differ food intake   
One 4th day ­ hunger score between 1-2 h after 10% 
breakfast vs 25% protein breakfast (10% P 1.6 ± 0.4 
vs 25%: 0.5 ± 0.3) 
Note: ­ refers to increase or high or up, ¯ refers to decrease or low or down  (Continue) 
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Author & Year Title Subjects Research Design Response 
Martens et.al., 
2013, Am J Clin 
Nutr, 97: 86-93 
(Martens, Lemmens 
& Westerterp-
Plantenga, 2013) 
 
Protein leverage 
affects energy 
intake of high-
protein diets in 
human 
- Human (40 men, 39 
women) 
- Age 34.0 ± 17.6 y 
- BMI 23.7 ± 3.4 kg 
m-2) 
 
- Single-blind crossover 
design 
- 5%, 15% and 30% protein 
diet used 
- Three conditions, 12 days for 
each 8 wk interval in between  
- Protein source whey or soy 
- breakfast, lunch and dinner 
ad libitum 
- Energy intake was ¯ in 30% P compare to 5% or 
15%  
- Protein intake varied according to the amount of 
protein in the diet.    
- Fluctuations in hunger and desire to eat were more 
consistent in 30%P compare 5% and 15%P  
- Bodyweight gradually decreased in all three 
conditions 
 
 
Note: ­ refers to increase or high or up, ¯ refers to decrease or low or down  
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1.4 Impacts of different types of protein on food intake: 
Protein is an indispensable macronutrient, and as a source of amino acids, protein is necessary 
for many biological processes.  As discussed above, increase % protein in the diet decreases 
food intake in many organisms (Huang et al., 2013; Sorensen et al., 2008). Thus, increasing 
the proportion of protein in the diet can play a role in weight loss as well as weight maintenance 
(Gosby et al., 2014). Dietary protein intake induces the release of complex signals from the 
gut, including short peptides and free amino acids that are derived by luminal digestion and act 
on local amino acid-sensitive receptors or via intracellular metabolism to control the release of 
peptide hormones and local neuronal activity to modulate macronutrient metabolism as well as 
appetite and satiety (Journel et al., 2012). It is well established that protein is more satiating 
compared to carbohydrate and lipid, but it is less clear whether some proteins are more satiating 
than others. Some human and animal studies have compared different protein types in terms of 
their effects on food intake and satiety. A comparison of three types of protein in humans found 
satiety was greater after the consumption of a fish meal compared to a beef or chicken meal, 
and the satiety produced by the fish meal declined more slowly than other meals (Uhe, Collier 
& O'Dea, 1992). In another comparison of six different types of protein, Lang et al. did not 
observe significant differences among egg albumin, casein, gelatin, soy, pea and wheat gluten 
(Lang et al., 1998). Another study in humans found that energy intake fell by 10% after a whey, 
soy or gluten protein preload compared with an isoenergetic glucose preload (Bowen, Noakes 
& Clifton, 2006). Interestingly, all protein preloads suppressed postprandial levels of the pro-
appetite hormone ghrelin and elevated postprandial levels of the satiety hormones GLP-1 and 
CCK (Bowen, Noakes & Clifton, 2006). Thus, in this study protein, regardless of its origin, 
suppressed appetite, which led to lowered food intake.  
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1.5 Whey and Casein protein:  
From the preceding, it is apparent that dietary protein suppresses food intake and some types 
of protein may be more effective than others in doing this. Two proteins that have been 
compared in previous studies are milk-derived casein (from the curds fraction) and whey (from 
the soluble fraction). Based on the speed of protein digestion and absorption, whey is 
considered a relatively ‘fast’ protein, whereas casein is considered a ‘slow’ protein (Boirie et 
al., 1997). Hall et al. reported that a whey protein preload more effectively suppressed food 
intake, and increased postprandial plasma CCK, GLP-1 and GIP when compared to a casein 
preload (Hall et al., 2003). Several studies have compared the impacts of whey and casein on 
food intake, the serum levels of gut metabolite hormones and plasma metabolites (Table 1.2). 
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Table 1.2 Studies discussing the role of whey and casein protein on food intake and appetite regulation 
Author & Year Title Subjects Research Design Response 
Veldhorst et al., 
2009, Physiology 
& Behavior 96, 
675-682 (Veldhorst 
et al., 2009) 
Dose-dependent 
satiating effect of 
whey relative to 
casein or soy 
- Human, 11 male and 
14 females 
- Age 22 ± 1 years, 
BMI 23.9 ± 0.3 
kg/m2  
  
- Randomised, single-blind  
- Subjects attended six occasion 
Each occasion single protein, 
three different protein (whey, 
casein, soy). High 25%P and 
low ten %P, %C fixed at 55% 
- At 10%P level Whey ¯ hunger compare to Casein 
and Soy 
- 25%P level no difference of appetite 
- Whey triggered GLP-1 and insulin compared with 
Casein and soy. 
 
McAllan et.al., 
2014. PLOS ONE, 
9 (2) (McAllan et 
al., 2014) 
 
Protein quality and 
the protein to 
carbohydrate ratio 
within a high-fat 
diet influences 
energy balance and 
the gut microbiota 
in C57BL/6J mice. 
Male, ten weeks old 
C57BL/6J mice, 5 or 
4 mice per cage. Ten 
mice per group 
- Study-1, 21week study:  
- n =10 per group 
- Casein 20% in LFD and HFD. 
- Whey 20%/ 30% or 40% in 
HFD 
Study-2 for 7 weeks: 
- n = 8 per group LFD (casein 
20%) or LFD (WPI 20%)  
- WPI ­ lean mass and  ¯ fat mass compares to 
similar energy content casein  
- In WPI group HFD ­ plasma leptin and ¯ TG. 
- WPI ­ Lactobacillaceae and ¯ Clostridiaceae 
- Highest WPI P/C ratio ¯ weight gain, ¯ fat mass, 
¯ plasma TG, ¯ non-esterified FA, ¯ plasma 
glucose, ¯ leptin, ­  lean mass, ­ oxygen 
consumption    
Hall et.al. 2003, Br 
J Nutr, vol. 89, 
no. 2, pp. 239-48 
(Hall et al., 2003) 
 
Casein and whey 
exert different 
effects on plasma 
amino acid profiles, 
gastrointestinal 
hormone secretion 
and appetite 
- Human 
- Study 1: 8 male, 8 
female, Age 22 ± 2.0, 
BMI 21.7 ± 2.0   
 
 Study 1: Isoenergetic high 
protein (48g) preload contained 
then offered buffet meal then 
2nd and 3rd choice of sandwich 
 
- Whey preload ¯ food intake compares to casein 
- Whey preload ¯ desire to eat compared to casein  
- Whey preload ­ plasma AA concentration over 3h 
28% compared to casein  
-  
(Continue) 
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Author & Year Title Subjects Research Design Response 
  Study 2: 8 female, 
one male, Age 25 ± 
2.4, BMI 22.6 ± 1.5 
Study 2: After preload, a cold 
lunch supplied (42 kJ kg-1 BW) 
buffet-style meal.  
- Whey preload ­ plasma CCK 60%, GLP-1 65% and 
GIP 36% 
 
 
 
 
 
 
 
 
 
 
 
 
Note: ­ refers to increase or high or up, ¯ refers to decrease or low or down  
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1.6 Amino acids and food intake 
Dietary protein and amino acids, including glutamate, generate signals involved in the control 
of gastric and intestinal motility, pancreatic secretion, and food intake (Morell & Fiszman, 
2017). This signal includes the postprandial release of hormones and neuropeptides in the GI 
tract. The aromatic amino acid, L-Phenylalanine, an agonist of the Calcium Sensing Receptor 
(CaSR), suppresses food intake in mice and rats by stimulating the release of the gut hormones 
GLP-1 and PYY and reducing appetite hormone ghrelin in plasma (Alamshah et al., 2017). 
Both type and quality of protein can influence satiety signal and dietary intake. The quality of 
proteins depends upon the amino acid composition; proteins rich in a broad spectrum of 
essential amino acids are considered to be of high quality. 
Increasing protein in the diet suppresses food intake and subsequently promotes body weight 
maintenance. It is not clear yet how protein modulates satiety, appetite and food intake. Recent 
studies suggested that amino acid products of protein digestion may modulate appetite via 
either peripheral and/or central mechanisms (Fromentin et al., 2012). Studies also suggested 
different types of protein exert variable effects on food intake and appetite control (Hall et al., 
2003; Pezeshki, Fahim & Chelikani, 2015; Veldhorst et al., 2009); hence it may be that amino 
acid composition of protein plays an important role to regulate appetite. Some recent studies 
implicate protein hydrolysates and key amino acids as regulators of appetite control (Table 
1.3).    
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Table 1.3 Some recent studies reflecting the role of protein hydrolysates and amino acids on food intake 
Author & Year Title Subjects Research Design Response 
Mizushige et al., 
2017. Biomed Res. 
Vol 38. No.6 351-
357  
Fish protein hydrolysate 
exhibits anti-obesity 
activity and reduces 
hypothalamic 
neuropeptide Y and 
agouti-related protein 
mRNA expressions in 
rats 
- Male Sprague 
Dawley rats 
(5wks) 
- Exp. 1 (n = 18), 
- Exp. 2 (n = 12) 
 
Exp. 1: 6 rats in each group, 
three groups, Alaska Pollack 
Protein hydrolysate (APP) by 
IP, two times day-1 (dose 0, 
100, 300 mg kg-1 BW).  
Exp. 2: 12 rats, 2 groups, 
APP by IP, 2 times day-1 
dose (0 or 300 mg kg-1 BW).  
- APP hydrolysate ¯ body weight and white adipose 
tissue (dose-dependent) 
- APP hydrolysate ¯ food intake 
- ¯ mRNA expression of NPY and AgRP in the 
hypothalamus 
- ¯ appetite ­ basal energy expenditure by skeletal 
muscle hypertrophy 
Chen et.al., 2018, 
Biosci Biotechn 
Biochem, vol. 82, 
no. 11, pp. 1992 – 
1999 
Wheat gluten 
hydrolysate potently 
stimulates PYY 
secretion and suppresses 
food intake in rats 
- Male 134 
Wister rats (7 
Wks) single 
housed  
- Hydrolysate: WGH, LAH, 
PPH, SPH 
- Fasted 12 hrs., Preload of 
hydrolysate 1g kg-1 BW, 
exposed to food  
- Preload of WGH ¯ food intake compares to other  
- PYY after 2 & 3 hrs ­ in WGH compare to control 
and LAH  
- WGH potentially stimulated GLP-1 secretion than 
LAH 
Zapata et.al., 2018, 
J Nutr Biochem, 
vol. 65, pp. 115-
127 (Zapata et al., 
2018) 
Tryptophan restriction 
partially recapitulates 
the age-dependent 
effects of total amino 
acid restriction on 
energy balance in diet-
induced obese rats 
- 64 Male Sprague 
Dawley rats 
- 5 WKs on high-fat diets 
- Eight rats per group, four 
groups 
- AA supplements as %P (15% 
P considered) 
- AA restriction (5% AA in 
food) 
- Total AA restriction ­ food intake both young & old 
- L-Trp restriction transiently ­ food intake  
- Total AA restriction ­ energy expenditure partly 
through ­ b2-AR & FGF-21 in brown fat, L-Trp 
restriction with young rat match but the not old match 
- Total AA restriction decreased lean mass by 3% 
compared to control 
(Continue) Note: ­ refers to increase or high or up, ¯ refers to decrease or low or down  
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- L-Trp restriction (67% 
restricted) 
- His restriction (67% 
restricted) 
- Treatment duration 3 wks 
- 29 wks obese rat same 
treatment 
- Total AA restriction ­ fasting C peptide and leptin 
compare to control 
- Total AA restriction ­ fasting and postprandial FGF-
21  
       
 
 
 
 
 
 
 
 
 
Note: ­ refers to increase or high or up, ¯ refers to decrease or low or down  
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1.7 Fibroblast Growth Factor 21 (FGF-21): 
Fibroblast Growth Factors (FGFs) play important roles in cell growth, differentiation, 
embryonic development, angiogenesis, and healing of wound (Beenken & Mohammadi, 2009). 
There are 22 members of FGF gene family in human (FGFs 1-23; FGF15 is an orthologue of 
human FGF19), which generally secret as heparin-binding proteins that interact with relevant 
FGF receptors (FGFRs) on the cell surface to elicit signal transduction (Angelin, Larsson & 
Rudling, 2012). Heparin sulphate glycosaminoglycans act as a co-factor to bind FGFs with 
activate cell surface tyrosine kinase FGF receptors (FGFR) 1–4. These types of FGFs are 
known as canonical FGFs, and they work in an autocrine and paracrine mechanisms (Ornitz, 
2000). By contrast, the FGF19 subfamily which includes FGF19, FGF21 and FGF23 have 
lower heparin-binding affinity due to lack of heparin-binding domain, enable their ability to 
enter the circulatory system and act as hormones (Angelin, Larsson & Rudling, 2012; Goetz et 
al., 2007). On the other hand,  the FGF19 subfamily requires a co-receptor named Klotho to 
bind to their receptors and thus activate specific cytoplasmic signalling transduction pathways 
(Fukumoto, 2008; Kurosu & Kuro, 2009; Urakawa et al., 2006). Klotho isoforms are expressed 
in limited tissue and cell types, directing the metabolic activity of the FGF19 subfamily to these 
specific tissues (Kurosu et al., 2007).  
 
FGF 21 is one of the members of an endocrine subfamily of FGFs that coordinates multiorgan 
energy metabolism, especially glucose and lipid metabolism (Fisher & Maratos-Flier, 2016; 
Woo et al., 2013). Mounting evidence suggests that FGF 21 can alleviate many metabolic 
disorders such as atherosclerosis, cardiovascular diseases, and metabolic syndrome (Fisher & 
Maratos-Flier, 2016; Jin, Lin & Xu, 2016; Salminen, Kaarniranta & Kauppinen, 2017; Woo et 
al., 2013). Beside multiorgan energy metabolism and alleviation of metabolic disorder, higher 
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levels of FGF 21 appear to promote health span and life expectancy (Youm et al., 2016; Zhang 
et al., 2012). 
 
FGF 21 robustly expressed in liver, and it is also expressed in several other key metabolic 
tissues, including the gut, brain, adipose tissue, muscle, and pancreas (Markan et al., 2014; 
Potthoff & Finck, 2014). Recent studies suggest that in addition to its role in multiorgan energy 
metabolism, FGF 21 is the first known endocrine signal activated by protein restriction (De 
Sousa-Coelho, Marrero & Haro, 2012; Laeger et al., 2014; Morrison & Laeger, 2015). The 
findings of some of the key studies that relate dietary composition, plasma FGF-21 levels and 
dietary intake provided in Table 1.4. 
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Table 1.4.  Some key studies reflect dietary intake and influence on FGF 21 
Author & Year Title Subjects Research Design Response 
Solon-Biet et al., 
2016, Cell 
Metabolism 24, 
555-565 (Solon-
Biet et al., 2016) 
Defining the 
Nutritional and 
Metabolic Context of 
FGF21 Using the 
Geometric 
Framework 
- Three weeks old 
Male and female 
C57BL/6J mice 
- Eight weeks old 
male C57BL/6J 
mice for acute 
study 
 
- Total 858 mice, ad libitum 
access to one of 25 diets 
varying in protein, 
carbohydrate, fat and energy 
density. 
- Low, medium and high energy 
density 
- Culled 183 mice across diet 
treatment after 15 months 
- Reduced protein intake robustly ­ FGF-21 
- Consuming protein < 5 KJ /day, consistently ­ 
hepatic FGF21 mRNA expression and circulating 
FGF21 
- Plasma FGF-21 positively correlated with 
carbohydrate and no detectable effect of fat and 
energy intake. 
- Circulating BCAA negatively correlated with FGF-
21 
Gosby et al., 2016. 
PLOS ONE, 11 (8) 
(Gosby et al., 2016) 
 
Raised FGF-21 and 
Triglycerides 
Accompany 
Increased Energy 
Intake Driven by 
Protein 
Leverage in Lean, 
Healthy Individuals: 
A Randomised Trial 
- Human, lean and 
healthy sux male 
and 16 females, 
(BMI = 18-25 kg 
m-2) 
- Three 4-day periods in house 
dietary study, the single-sex 
group at a time 
- Each 4-day ad libitum access to 
10%, 15% or 25% protein 
- Participants were blinded to 
the treatment 
- 1 hour supervised walk 
each day 
- Plasma FGF-21 ­ 1.6-fold at 10%P diet treatment 
compared to 15% P diet and 6-fold compared to 
25%P diet 
- Fasting plasma ghrelin, GLP-1 and CCK did not 
change with % P changes in diet. 
- Fasting glucose did not differ between 10%, 15% 
and 25% protein diets  
- Serum TG ­1.2-fold and 1.5-fold at 10%P diet 
compared to 15%P and 25%P diet respectively.  
    Note: ­ refers to increase or high or up, ¯ refers to decrease or low or down          (Continue)
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Author & Year Title Subjects Research Design Response 
Laeger et al., 
2014, J Clin 
Invest. 124 (9), 
3913 – 3922 
(Laeger et al., 
2014) 
FGF21 is an endocrine 
signal of protein 
restriction 
- Human, 25 male 
and female, age 
18 to 35 and BMI 
19-30 
- Rats (Sprague 
Dawley) 
- C57BL/6J mice 
- GCN2 and 
PPARa or FGF-
21 deficient mice 
C57BL/6J  
- Weight stabilised 13-25 days, 
divided into three diet group 
(5%P, 15%P and 25% P), 
overfed for eight weeks 
- An isocaloric diet with fixed 
fat content. % P and % CHO 
varied. Casein source of 
protein.  
- The ketogenic diet contained 
4.7% P and 93.4% fat 
Human study: 
- ­ Plasma FGF-21 by 171% after 28 days feeding 
of low protein diet 
Rodent study: 
- At low P diet ­ food intake, ­ adiposity, ­ hepatic 
3-Phosphoglycerate dehydrogenase and 
asparagine synthetase in rats 
- Low protein intake ­ serum FGF-21 and hepatic 
FGF-21 mRNA (7 fold) expression 
- Low protein-induced c FGF-21 to depend on 
GCN2 and PPARasignalling.   
Larson et al., 
2019, 
Endocrinology. 
160 (5), 1069 – 
1080 (Larson et 
al., 2019) 
Fibroblast growth factor-
21 controls dietary Protein 
intake in male mice 
- Male mice 8-20 
per group 
- Age-matched 
adult C57BL/6J 
- b-klotho lacking 
in neuron mice 
- Littermate control 
- Administration of Saline or 
FGF-21(1mg kg-1 or 0.2 mg 
kg-1) by IP, 
- Measured food intake 
overnight  
- Only P or C or F diet were 
provided 
- FGF-21 ¯ sucrose intake ­ chow intake 
- FGF-21 ­ P intake, ¯ C intake 
- FGF-21 has no impact on energy intake and body 
weight change 
- FGF-21 administration at a low dose for seven 
days  ­ P intake, ¯ C intake, ¯ body weight, ­ 
energy intake   
Note: ­ refers to increase or high or up, ¯ refers to decrease or low or down  
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1.8 Gut metabolite hormones and food intake: 
Gut hormones play key roles in appetite control, energy metabolism and regulation of food 
intake. The gut hormone secretin was the first chemical messenger to be identified as a 
hormone more than a century ago, forming the basis of the whole field of endocrinology 
(Bayliss & Starling, 1902). Subsequently, most of the gut hormones discovered as ‘endocrine 
principles,’ which in many cases were later identified as hormones (Engelstoft & Schwartz, 
2016). These peptide hormones regulate functions of the gastrointestinal (GI) tract including 
the endocrine pancreas, and control metabolism throughout the body by regulating the 
functions of various organs, including muscle, fat, liver and the central nervous system (CNS), 
where they, for example, regulate appetite (Ceranowicz, Warzecha & Dembinski, 2015). Some 
of these hormones are known as anorexigenic (appetite-suppressing), e.g. Glucagon-Like 
Peptide (GLP) -1), Peptide Tyrosine Tyrosine (PYY), Cholecystokinin (CCK), Gastric 
Inhibitory Polypeptide (GIP) and others are orexigenic (appetite-stimulating), e.g. Ghrelin.  
Each gut hormone has a unique distribution pattern along the length of the GI tract, such as 
ghrelin in the stomach, and GLP-1 in the small and large intestine. In addition, gut peptide 
hormones are produced by discrete subpopulations of enteroendocrine cells in the GI tract 
(Habib et al., 2012). The gut segment and cell types of origin of key gut metabolite hormones 
are shown in Table 1.5. 
Table 1.5. Gut metabolite hormones, primary secretion sites and enteroendocrine cells 
Hormones Primary sites Enteroendocrine cells 
Ghrelin Stomach X/A – like cells 
GLP-1 Ileum/colon L cells 
PYY Ileum/colon L cells 
CCK Duodenum/ jejunum I cells 
GIP Duodenum/ jejunum K cells 
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1.8.1 Ghrelin: 
Ghrelin is a well-known peripherally-derived orexigenic hormone, which increases appetite 
and subsequently, food intake. The ghrelin gene produces preproghrelin, a 117 amino acid 
peptide which is converted to several smaller biologically active peptides. There are two most 
abundant forms of ghrelin, i.e. acylated ghrelin and des-acyl ghrelin, both composed of 28 
amino acids (Kojima et al., 1999).  
 
The ghrelin receptor is a G-protein-coupled receptor (GPCR) that can form heterodimers with 
other key components of body weight regulation such as the melanocortin receptor 3 (MC3) 
and GPR83 (Al Massadi et al., 2017). MC3 and GPR83 are co-localized with the ghrelin 
receptor in ARC neurons (Muller et al., 2013; Rediger et al., 2011). The interaction between 
MC3 and the ghrelin receptor promotes MC3 signalling while simultaneously inhibiting signals 
from ghrelin receptors (Rediger et al., 2011). GPR83 heterodimerized with the ghrelin receptor 
and repressed the activity of the receptor (Muller et al., 2013). Ghrelin receptor is also 
expressed in NPY/AgRP neurons (Zigman et al., 2006). An in vivo imaging showed that 
circulating fluorescent-labelled ghrelin (F-ghrelin) reached the hypothalamus by passive 
diffusion through the fenestrated capillaries of the median eminence, which approached to 
ventromedial part of the ARC, and finally targeted NPY/AgRP neurons to develop a metabolic 
response (Schaeffer et al., 2013).   
 
Gastric ghrelin cells express several nutrient-sensing receptors such as CaSR, Free Fatty Acid 
Receptor 2 (FFAR2), FFAR4, Guanine Nucleotide-binding Protein 3 (GNAT3) and 
HydroxyCarboxylic Acid Receptor 1 (HCAR1) (Depoortere, 2014; Elliott et al., 1993; Steinert 
et al., 2017). All these receptors express basolateral aspects of ghrelin cells; they are probably 
stimulated mainly by metabolites entering the laminal propria from circulation (Steinert et al., 
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2017). All macronutrients inhibit postprandial ghrelin secretion, but their potency is different, 
with protein considered most potent, followed by carbohydrate, then lipid (Foster-Schubert et 
al., 2008). Circulating amino acids may inhibit ghrelin secretion via CaSR (Engelstoft et al., 
2013). Types of carbohydrate influence ghrelin secretion; lactose intake suppressed ghrelin 
level more compared to glucose intake (Bowen et al., 2006) and glucose intake suppressed 
ghrelin level more than did fructose (Teff et al., 2004). Studies also revealed that only fatty 
acids with a chain length greater than or equal to C12 inhibit ghrelin secretion (Degen et al., 
2007; Feltrin et al., 2006). 
 
1.8.2 GLP-1 
Glucagon-like peptide (GLP)-1 is a peptide hormone secreted from enteroendocrine L cells of 
the distal small intestine in response to food intake. Most GLP-1 cells in the distal jejunum and 
ileum coexpress and secrete PYY; also, some GLP-1 cells co-express CCK, GIP, neurotensin, 
or secretin (Egerod et al., 2012; Habib et al., 2012; Steinert et al., 2017). GLP-1 is also 
produced in the central nervous system (CNS), predominantly in the brainstem, from where it 
transported throughout the brain to elicit metabolic, cardiovascular, and neuroprotective 
actions (Campbell & Drucker, 2013; Steinert et al., 2017)). Endogenous GLP-1 is rapidly 
degraded by the enzyme dipeptidyl peptidase-4 (DPP-4) to inactivate metabolites. As a 
consequence, it has a short circulating half-life of less than 10 min (Holst, 2007; Steinert et al., 
2017). GLP-1  and GIP exert their insulinotropic actions through a distinct, class B GPCR 
GLP-1R, which is highly expressed on islets b cells (Campbell & Drucker, 2013; Eissele et al., 
1992). GLP-1R also widely expressed in other islets cells (a and g) as well as other organs 
including the heart, abdominal vagal afferents, gastrointestinal tract and brain (Campbell & 
Drucker, 2013; Jazayeri et al., 2017).   
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GLP-1 is a satiety hormone secreted from L cells of the distal small intestine. Thus, intravenous 
infusions of GLP-1 reduced meal size in the absence of other observed effects in healthy-
weight men (Degen et al., 2006; Flint et al., 1998; Steinert et al., 2017). Plasma GLP-1 
concentrations are at their lowest levels after overnight fasting, increase rapidly during meals, 
and remain elevated between meals during the day (Carr et al., 2010; Elliott et al., 1993; 
Steinert et al., 2017). The macronutrient composition of the diet influences GLP-1 secretion. 
Oral loads of glucose and several other carbohydrates increase plasma GLP-1 levels, with peak 
values occurring rapidly, within 15-30 min of food intake (Carr et al., 2010; Elliott et al., 1993; 
Herrmann et al., 1995; Steinert et al., 2017). Intraduodenal-infusions of glucose also induce 
prompt increases in plasma GLP-1 levels (O'Donovan et al., 2004; Pilichiewicz et al., 2007).   
 
Oral ingestion of dietary protein or dietary lipid also induces increases in plasma GLP-1 
levels, but they typically produce slower-onset, more sustained increases than those observed 
in response to glucose (Bowen, Noakes & Clifton, 2006; Calbet & Holst, 2004; Campbell & 
Drucker, 2013; Carr et al., 2008).  
 
1.8.3 PYY 
PYY is another peptide hormone that is co-secreted with GLP-1 from intestinal L-cells. The 
apical microvilli of L-cells are in contact with the intestinal lumen which allow the L-cells to 
sense nutrients and other substances presented in the lumen. After ingestion of a meal L-cells 
enriched in basal endocrine granules allow secretion of hormones into the circulatory system 
to induce satiety (le Roux & Bloom, 2005). PYY, together with pancreatic polypeptide and 
neuropeptide Y comprises the PP family of peptides (Berglund, Hipskind & Gehlert, 2003; 
Stadlbauer et al., 2015). There are two forms of PYY which can be differentiate by two amino 
acids at the N-terminus of the peptide (Grandt et al., 1994). Thus, after its release from L-cells 
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PYY1-36 is rapidly converted to PYY3-36 by the plasma enzyme, DPP-4, which is responsible 
for the removal of  N-terminal Try-Pro (Mentlein et al., 1993; Stadlbauer et al., 2015). PYY3-
36 has a high-affinity as a agonist for the NPY2 receptor, which suppresses cyclic AMP and 
stimulates the mobilisation of intracellular calcium (Berglund, Hipskind & Gehlert, 2003; 
Michel et al., 1998). NPY2 receptors are expressed throughout the body, including several 
organs in CNS such as frontoparietal cortex, hippocampus, thalamus, the hypothalamus. In the 
peripheral nervous system, the NPY2 receptor is found in parasympathetic, sympathetic and 
sensory neurons and also in the intestine and certain blood vessels (Dumont et al., 1995; 
Simpson et al., 2012; Walther, Morl & Beck-Sickinger, 2011).  
 
Plasma PYY levels generally increase 15–30 min after a meal, attain their maximum after 60–
90 min, and remain elevated for several hours (Ballantyne, 2006; Batterham et al., 2003; 
Batterham et al., 2006; Steinert et al., 2017). Postprandial PYY and GLP-1 profiles are 
dissimilar because DPP-4 activates PYY but inactivates GLP-1 (Eissele et al., 1992; Mortensen 
et al., 2003; Steinert et al., 2017). 
 
Chronic administration of  PYY3-36 via either an osmotic mini-pump or continuous intravenous 
infusion significantly reduces body weight and adiposity in normal and obese rodents (Vrang 
et al., 2006). Administration of PYY3–36 has similar suppressive effects on food intake in obese 
and non-obese subjects (Batterham et al., 2003; Sloth et al., 2007). PYY3–36 increases energy 
expenditure by increasing postprandial thermogenesis, resting metabolic rate and 24-h 
respiratory quotient (Guo et al., 2006; Sloth et al., 2007). A significant number of studies have 
revealed PYY suppress food intake and appetite control, but it is not clear how this anorectic 
effect works. 
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1.8.4 CCK 
Cholecystokinin was the first gut-derived peptide hormone to be identified as a satiety hormone 
(Gibbs, Young & Smith, 1973). In rodent enteroendocrine CCK cells also express and secrete 
ghrelin, GLP-1, PYY, GIP, neurotensin and secretin (Egerod et al., 2012). CCK circulates as 
several peptide forms in different length and varies between species. In human, CCK-58, CCK-
39, CCK-33 and CCK-8 have been identified (Eberlein, Eysselein & Goebell, 1988). The 
circulating half-life varies between fragments; however study determined a half-life in humans 
approximately 2.5 min (Thompson et al., 1975). One of the major forms is the 58-residue form 
CCK-58, which accounts for 80% of the total CCK in the human duodenal mucosa, the relative 
amounts of small forms increase towards distal jejunum (Eberlein, Eysselein & Goebell, 1988).  
There are two subtypes of CCK receptor, CCK-1 and CCK-2; both of these receptors are class 
1 GPCR (Simpson et al., 2012). CCK has pro-satiety effects that are mediated by CCK-1R 
receptors on vagal afferents in the duodenum, which signal to the nucleus of the tractus 
solitarius in the brain to reduce the feeling of hunger (Chandra & Liddle, 2007).  Breakdown 
of proteins to free amino acids and triglycerides to fatty acids (specially > C12) is required for 
normal macronutrient-induced CCK secretion (Ballinger & Clark, 1994; Colombel et al., 1988; 
Feinle et al., 2003). One human study demonstrated following luminal perfusion of the small 
intestine with a mixture of individual amino acids, L-Phe, L-Met, L-Trp, and L-Val were much 
more effective in increasing plasma concentrations of CCK when compared to a mixture that 
included L-His, L-Leu, L-Ile, L-Lys, and L-Thr, which had no effect (Colombel et al., 1988). 
In a later human study, L-Phe was shown to powerfully increase plasma concentrations of CCK 
and reduce food intake (Ballinger & Clark, 1994).  
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1.8.5 Leptin 
Leptin is a peptide hormone that regulates energy expenditure, body weight, fat mass and 
feeding behaviour. Leptin is mainly produced in adipose tissue (Campfield, Smith & Burn, 
1996; Zhang et al., 1994), circulating leptin levels increase with total body adiposity and leptin 
acts to reduce adiposity by decreasing food intake and increasing energy 
expenditure(Campfield, Smith & Burn, 1996).  Leptin acts on ARC neurons in the 
hypothalamus to increase the production of anorexigenic proopiomelanocortin (POMC) while 
suppressing the production of orexigenic neuropeptide Y (NPY)/Agouti-related protein 
(AgRP) (Kwon, Kim & Kim, 2016). Via this mechanism, leptin suppresses energy intake and 
stimulates energy expenditure, leading to a reduction in stored body fat (Kwon, Kim & Kim, 
2016). Leptin belongs to the long-chain helical cytokine family (Hopkins et al., 2016) and 
exerts its regulatory effects on energy homeostasis through its receptors which have a wide 
tissue distribution that includes the CNS in both humans and rodents (Gotoda et al., 1997). To 
date, six isoforms of the leptin receptor have been identified in rodents (LepR a–f), all 
possessing the extracellular domains necessary for ligand binding (Bates & Myers, 2004; 
Tartaglia et al., 1995; Zhang et al., 1994). Leptin receptors are categorised into three groups: 
secreted, short, and long isoforms. Only long isoforms support cellular leptin signalling 
intracellularly (Baumann et al., 1996; Rosenblum et al., 1996).   
 
Leptin receptors regulate food intake and energy homeostasis by JAK-STAT signalling 
pathway. Leptin binds to its receptors and initiates the signalling process through the sequential 
phosphorylation of Janus kinase (JAK), a protein tyrosine kinase, and transcription factors 
known as Signal Transducers and Activators of Transcription (STATs) (Kwon, Kim & Kim, 
2016). Leptin signalling induces phosphorylation of STAT1, STAT3, STAT5 and STAT6. It 
is understood that leptin might have mediate its anorectic effect by inducing STAT3 and 
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possibly STAT5 (Baumann et al., 1996). STAT3 is widely expressed in the CNS. Neuron-
specific STAT3 deletion resulted in hyperphagia, severe obesity, diabetes and hyperleptinemia 
(Gao et al., 2004). 
 
1.9 Gut microbiome and Food intake:   
The human intestine is a harbour of diverse, complex microbial community which is known as 
gut microbial flora or gut microbiome (Hooper & Gordon, 2001; Tilg & Kaser, 2011).  
Food intake also dependent on gut microbiome. Several recent studies with mouse models and 
in humans have demonstrated that the intestinal microbiome plays an important role in host 
metabolism by regulating nutrient and total energy absorption and by modulating gut endocrine 
functions. On the other hand, dietary pattern, types of diet, macronutrient composition and fibre 
contents in diets influence gut microbial flora (David et al., 2014; De Filippo et al., 2010; Eid 
et al., 2017; Muegge et al., 2011; Schnorr et al., 2014; Wu et al., 2011).  Whey protein has been 
reported previously to adjust the balance of the gut microbial flora by increasing faecal 
Lactobacilli and Bifidobacteria counts and reducing faecal Clostridia counts (McAllan et al., 
2014; Sprong, Schonewille & van der Meer, 2010).  
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1.10 Aims and Hypotheses: 
Increasing the concentration of protein in the diet with corresponding reductions in 
carbohydrate and/or lipid content suppresses food intake – the protein leverage effect (PLE).  
However, as noted above, proteins differ in their suppressive effects on appetite (Uhe, Collier 
& O'Dea, 1992). Similarly, the addition of protein hydrolysates or addition or restriction of 
particular amino acid subgroups has distinct effects on appetite.  
Furthermore, the molecular and cellular basis for the protein leverage effect is unknown. PLE 
arising from the ingestion of different proteins may be dependent on the differential impacts of 
particular L-amino acids or amino acid mixtures. Thus, protein-derived L-amino acid signals 
may control the release of gut-derived appetite-regulating hormones, including the pro-appetite 
hormone ghrelin or satiety hormones CCK, GLP-1, PYY and Leptin. After absorption and 
metabolism, amino acids may also modulate the serum levels of the centrally acting appetite 
hormone FGF-21 or act directly upon central appetite control centres. 
 
Therefore, the aims and hypotheses of this thesis are: 
1. To determine whether total food intake differs between diets that differ in protein type 
and concentration, focusing on whey-based and casein-based diets at different levels 
of %P.  
 
Null Hypothesis: There will be no differences in food intake according to the type of 
protein in the diet regardless of %P. 
  
2. To test whether the dietary levels of carbohydrate and lipid modify the impact of high 
or low %P on food intake.  
 
Null Hypothesis: Dietary protein will have the same suppressive effect on food intake 
in the presence of higher levels of either dietary carbohydrate or fat. 
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3. To determine the impact of dietary protein choice at different %P levels on the levels of 
gut hormones in serum, serum metabolites, as well as key urinary and tissue metabolites 
that are sensitive to food intake.   
 
Null Hypotheses: Differences in dietary protein source will not impact the levels of gut 
metabolite hormones, serum metabolites, key urinary and tissue metabolites. 
 
4. To determine whether individual amino acids in the diet influence food intake and the 
serum levels of gut metabolite hormones  
 
Null Hypothesis: amino acids composition in the protein is not associated with food 
intake has no impact on gut metabolites hormones and serum metabolites.  
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General Materials and Methods 
2.1 Animals and husbandry 
Mice were used as subjects in study 1 (Chapter 3), study 2 (Chapter 4) and study 3 (Chapter 
5). All mice were housed in 12-hour light: 12-hour dark cycles under controlled temperature 
and humidity in a rodent facility at the University of Sydney. I used mice that were 6 months 
or older in all studies to ensure that intake energy was used primarily for basal metabolism 
rather than growth. Before the start of the studies, all mice had ad libitum access to the standard 
chow diet (Digestible Energy 14.2 MJ/kg, protein 23% of DE, Lipid 12% of DE and 
Carbohydrate 65% of DE) and water. We provided standard environmental enrichment aids 
including an igloo as a place to hide, rolls of tissue paper and wooden chewing blocks. Mice 
were monitored twice per week, if we had identified any sign of development of Ulcerative 
Dermatitis (UD) because of fighting or overgrooming we treated those mice with Cerenia 
(Maropitant Citrate 30 mg/kg Bodyweight, Zoetis Services LLC) with Ringer’s solution by 
Intraperitoneal (IP) injection and application of Amacin (contains: Polymixin B, Sulfacetamide 
Sodium, Prednisolone; Jurox Pty Limited) antibiotic cream on the wound/ infected area. 
Infected mice were isolated during treatment and were housed singly during the study period 
until euthanasia.    
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Study 1   
We used 16 male C57BL/6J mice between 10 months to 18 months of age for Study 1. They 
were sourced from Laboratory Animal Services (LAS), University of Sydney. Age-matched 
mice were housed continuously as cage mates (two per cage) in a rodent facility at School of 
Molecular Bioscience Building, University of Sydney. All mice had ad libitum access to food 
and water.  
 
 
Study 2 
For studies described in Chapter 4, we purchased 48 male C57BL/6J mice at weeks of age from 
a commercial supplier (Australian BioResources, Moss Vale, NSW, 2577, Australia). Upon 
arrival in the Animal House they were randomly distributed in age-matched groups of two mice 
per cage (GM 500 Mouse IVC Green Line cage, Techniplast, Italy) and given ad libitum access 
to food (Chow diet) and water in the Charles Perkins Centre (CPC) University of Sydney rodent 
facility on a 12 h light: 12 h dark cycle under controlled temperature and humidity. Mice were 
aged for four months to bring them up to the expected age of six months. During the aging 
process, we monitored the health and wellbeing of all mice twice per week  
 
Study 3  
I used 48 male C57BL/6J mice for Study 3, described in Chapter 5. They were sourced at seven 
weeks of age from a commercial supplier (Australian BioResources, Moss Vale, NSW, 2577, 
Australia). Upon arrival in the Animal House we randomly distributed those in age-matched 
groups of two mice per cage (GM 500 Mouse IVC Green Line cage, Techniplast, Italy) that 
received ad libitum access to food (Chow diet) and water in the Charles Perkins Centre (CPC) 
rodent facility on a 12 h light: 12 h dark cycle under controlled temperature and humidity. Mice 
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were aged for four months to bring them up to an expected age of six months. During the aging 
process, we monitored the health and wellbeing of mice two times per week.  
 
2.2 Euthanasia  
In the adverse event or at the end of the study, mice were euthanised by CO2 inhalation or 
anaesthetised by Isoflurane inhalation then euthanised by exsanguination. Mice kept in their 
home cage during CO2 inhalation euthanasia, the cage was placed inside the CO2 gas chamber, 
and the CO2 tube was inserted through the water bottle hole of the cage. The cage was slowly 
filled up by 100% CO2 at a rate to fill 10 - 20% chamber volume per minutes as per the 
recommendation of ACLAM (Artwohl et al., 2006).   
 
Study 1 
Mice were euthanised by CO2 inhalation and carcasses were disposed of according to policy 
and procedure of LAS, University of Sydney. 
 
Study 2 and 3  
We used the Stinger anaesthetic system (AAS, Gladesville, NSW 2111, Australia) to euthanise 
mice by Isoflurane inhalation for study chapter 4 and 5. Mice anaesthetised by Isoflurane 
inhalation (Isoflurane 4%, Oxygen 0.6 L/min) then the blood sample was collected by cardiac 
puncture and mouse were euthanised by exsanguination. After confirmation of death, tissue 
samples were collected, and carcasses were disposed of in a designated place.    
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2.3 Diets 
Two types of mice diets used in all studies. 
i. Control chow diet 
ii. Experimental diets 
 
2.3.1 Control chow diets 
A fixed formulation diet for laboratory rats and mice fortified with vitamins and minerals to 
meet the requirements as a general ration for breeding and growth in all rat and mouse strains. 
We used control chow diets from commercial supplier Speciality Feeds Pty, Glen Forrest, WA, 
Australia. Lists of ingredients for control chow diets are; wheat, barley, lupins, soya meal, fish 
meal, mixed vegetable oils, canola oil, salt, Calcium carbonate, Di-calcium phosphate, 
Magnesium oxide, a vitamin and trace mineral premix.  
Table 2.1. Calculated nutritional parameters in control chow diet  
Nutritional parameters Amount 
Energy 
Total digestible energy (DE) 14 MJ/Kg 
% Protein-energy 23% of DE 
% Carbohydrate energy 65% of DE 
% Fat energy 12% of DE 
Nutrients 
and fibre 
% Protein  19% 
% Carbohydrate 59.90% 
% Fat 4.60% 
Crude fibre 5.20% 
Acid detergent fibre 7.7% 
Neutral detergent fibre 15.50% 
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2.3.2 Experimental diets 
Experimental diets were designed based on the American Institute of Nutrition (AIN) 93G diet. 
In all studies, when we referred to the macronutrient composition of diets, we always referred 
to % of Digestible Energy (DE) content.    In these modified diets either bovine milk casein or 
whey was used as a source of protein; sucrose, wheat starch and dextrinised starch used as a 
source of carbohydrate; soy oil and canola oil as a source of lipid. AIN 93G diet is suitable for 
animal growth, pregnancy and lactation, 200g/kg protein (casein >85%) are recommended in 
this diet (Reeves, Nielsen & Fahey, 1993).  
 
Cellulose has been used as a source of dietary fibre and assigned an energy density value of 0 
for these diets and inclusion level has been allowed to “float” to act as filler.   As per 
recommendation AIN 93G mineral mix and AIN 93G vitamin mix used in diets. Calcium 
carbonate used as a source of calcium and Potassium Di-hydrogen Phosphate used as a source 
of phosphate; also Potassium Sulphate, Potassium Citrate and Choline Chloride were 
supplemented in all diets. All study diets were manufactured in dry, pelleted form by Speciality 
Feeds Ltd, 3150 Great Eastern Highway, Glen Forrest, Western Australia 6071. 
Macronutrients, i.e. % Carbohydrate (%C), % Protein (%P) and %Fat (%F) in all experimental 
diets in this thesis would be % of DE unless it were stated differently.   
 
%C fixed diets for Study 1 and 2 
All experimental diets in these studies contained high digestible energy (17 MJ/Kg). We used 
casein and whey as the source of protein, %C content in diets was fixed at 50% of DE, so the 
amount of %F and %P varied with changes of %P in diets. As per the recommendation of 
AIN93G diets, all diets in this study were supplemented with DL-Methionine (3 g/Kg diet) to 
compensate sulphur-containing amino acid deficiency. We had used 33% P (Cat. no. SF13-
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009, SF13-048), 23% P (Cat. no. SF13-007, SF13-047), 13%P (Cat. no. SF13-008, SF13-048), 
10% P (Cat. no. SF15-005, SF15-006), 7.5% P (Cat. no. SF15-034, SF15-035) diet for this 
study. Detail of diet composition is below 
Table 2.2. Compositions of Casein and Whey diets in studies 1 and 2, in which % C were 
fixed (see Chapters 3 and 4).  
Diets Casein diets  Whey diets 
 33%P 23%P 13%P 10%P 7.5%P 33%P 23%P 13%P 10%P 7.5%P 
Digestible energy 
(MJ/ kg) 
17 17 17 17 17 17 17 17 17 17 
Protein  
(% DE) 
33 23 13 10 7.5 33 23 13 10 7.5 
Carbohydrate 
(% DE) 
50 50 50 50 50 50 50 50 50 50 
Lipid 
(% DE) 
17 27 37 40 42.5 17 27 37 40 42.5 
Crude Fibre (%) 0 5.5 11.1 15.9 17.1 0 5.5 11.1 15.6 16.9 
CaCO3 (g/kg) 13.1 13.1 13.1 13.1 13.1 13.1 13.1 13.1 13.1 13.1 
NaCl (g/kg) 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 
KH2PO4 (g/kg) 6.9 6.9 6.9 6.9 6.9 6.9 6.9 6.9 6.9 6.9 
K2SO4 (g/kg) 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 
Choline Chloride 
(75%) g/kg 
2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 
AIN93 vitamin 
mix (g/kg) 
10 10 10 10 10 10 10 10 10 10 
AIN93 trace 
minerals (g/kg)  
1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 
 
%F fixed diet for Study 2 
All experimental diets in this study contained high digestible energy (17 MJ/Kg). We used all 
experimental diets of study-1 except 33%P diets in this study; in addition, we also used lipid 
content fixed (27% of DE) diets. Similar to study-1, casein and whey were used as a source of 
protein. As per the recommendation of AIN93G diets, all diets in this study were supplemented 
with DL-Methionine (3 g/Kg diet) to compensate sulphur-containing amino acid deficiency. In 
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addition to study-1 diets, we used lipid content fixed 13% P (Cat. no. SF15-130, SF15-137), 
10% P (Cat. no. SF15-131, SF15-138), 7.5% P (Cat. no. SF15-132, SF15-139) diet in this 
study. Details of the composition of lipid fixed diets are below 
 
Table 2.3. Compositions of Casein and Whey diets in Study 2, in which % lipid was fixed 
(see Chapter 4).  
Diets Casein diets Whey diets 
 13%P 10%P 7.5%P 13%P 10%P 7.5%P 
Digestible energy (MJ/ kg) 17 17 17 17 17 17 
Protein (% DE) 13 10 7.5 13 10 7.5 
Carbohydrate (% DE) 60 63 65.5 60 63 65.5 
Lipid (% DE) 27 27 27 27 27 27 
Crude Fibre (%) 7.0 6.7 6.5 6.4 6.4 6.4 
CaCO3 (g/kg) 13.1 13.1 13.1 13.1 13.1 13.1 
NaCl (g/kg) 2.6 2.6 2.6 2.6 2.6 2.6 
KH2PO4 (g/kg) 6.9 6.9 6.9 6.9 6.9 6.9 
K2SO4 (g/kg) 1.6 1.6 1.6 1.6 1.6 1.6 
Choline Chloride (75%) g/kg 2.5 2.5 2.5 2.5 2.5 2.5 
AIN93 vitamin mix (g/kg) 10 10 10 10 10 10 
AIN93 trace minerals (g/kg)  1.4 1.4 1.4 1.4 1.4 1.4 
 
 
Study 3  
All experimental diets in this study contained moderate digestible energy (14 MJ/Kg).  Lipid 
content in the diets was fixed at 27% of DE, so the amount of carbohydrate and protein varied 
with changes of %P in diets. Diets in this study were not supplemented with DL-Methionine 
(3 g/Kg diet). We had supplemented some amino acids (L-Trp, L-Cys, L-Thr, L-Trp + L-Cys 
+ L-Thr) with10% casein diets, details of diets design in chapter 6. We had used 23% P (Cat. 
no. SF17-116, SF17-117), 10% P (Cat. no. SF17-118, SF17-119), 10%P casein supplemented 
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with L-Cys (Cat. No. SF17-120), 10%P casein supplemented with L-Trp (Cat. No. SF17-121), 
10%P casein supplemented with L-Thr (Cat. no. SF17-122), 10% P casein supplemented with 
L- Cys + L-Trp + L-Thr (Cat. no. SF17-123) diets for this study. Detail of diet composition is 
below 
Table 2.4. Compositions of Casein, Whey and Amino Acids supplemented Casein diets in 
Study 3, in which % lipid was fixed (see Chapter 5).  
Diets Casein  Whey  Casein supplemented with 
L-Cys L-Trp L-Thr L-Cys + 
L-Trp + 
L-Thr 
Diets 23%P 10%P 23%P 10%P 10%P 10%P 10%P 10%P 
Digestible energy  
(MJ/ kg) 
14 14 14 14 14 14 14 14 
Protein (% DE) 23 10 23 10 10 10 10 10 
Carbohydrate (% DE) 50 63 50 63 63 63 63 63 
Lipid (% DE) 27 27 27 27 27 27 27 27 
Crude Fibre (%) 21.9 21.1 21.2 21.0 21.6 20.9 21.2 21.8 
CaCO3 (g/kg) 13.1 13.1 13.1 13.1 13.1 13.1 13.1 13.1 
NaCl (g/kg) 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 
KH2PO4 (g/kg) 6.9 6.9 6.9 6.9 6.9 6.9 6.9 6.9 
K2SO4 (g/kg) 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 
Choline Chloride 
(75%) g/kg 
2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 
AIN93 vitamin mix 
(g/kg) 
10 10 10 10 10 10 10 10 
AIN93 trace minerals 
(g/kg)  
1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 
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2.4 Data collection 
2.4.1 Food intake 
Food intake was measured by manually weighing the contents of the food hoppers each week. 
While weighing food, negligible spillage of food was confirmed by visual examination on the 
bottom of cages. Most of the time, spillage was negligible (1.0 – 2.0 g /cage/week); if there 
was any considerable amount of feed spillage, we adjusted the amount as leftover. Food intake 
was measured once per week. To calculate food intake per day,  total weekly intake was divided 
by 7 to determine food intake per day. These values were then divided by the number of mice 
per cage (usually 2) to determine food intake per mouse per day.  
 
Study 1 
I measured food intake once per week between 12:30 to 14:00. Details of food intake 
measurement in chapter 3. 
 
Studies 2 and 3  
Food intake was measured once a week by weighing the contents of food hopper. For 
homogenous data collection, we strictly maintained the day and time of data collection.  
Occasionally we had used a customised sifter to separate leftover feed; the sifter easily fit with 
IVC cages and separate food particles and faecal waste from cage bedding. 
 
Preparation of blood collection tube 
Anti-coagulant coated 1.5 ml microfuge tubes were used to collect blood samples. Dipotassium 
Ethylenediaminetetraacetic acid (K2EDTA, Sigma Aldrich, Catalogue no. ED2P-100G) salt 
was used as an anticoagulant. 10 µl of K2EDTA  (concentration 40 mg/ml) solutions were 
aliquoted into 1.5 ml microfuge tubes (for 200 µl blood volume), the concentration of 
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anticoagulant K2EDTA in blood 2 mg/ml (J. A. Koepke  S. M. Lewis  C. E. McLaren N. K. 
Shinton  N. Tatsumi  R. L. Verwilghen, 1993). Microfuge tubes were dried overnight in a fume 
hood. Anticoagulant coated tubes were stored in a dry place at room temperature. 
2.5 Blood collection 
We have used two blood collection techniques during the study.  
1. Submandibular bleeding method  
2. Cardiac puncture 
 
2.5.1 Submandibular bleeding method 
A small vascular bundle at the back of the jaw characterises the cheek of mice (please see 
Figure 2.1). This is the point where the orbital veins, the submandibular vein, and other veins 
draining the facial region join to form the beginning of the jugular vein (Golde, Gollobin & 
Rodriguez, 2005).   
 
Fig. 2.1 Submandibular vein bleeding (Golde et.al. 2005)  
 
We hold mice by the scruff of the neck in the air to establish the most relaxed situation for the 
mouse, then gently clean the target area with alcohol wipes. 19G needle was used, firmly poked 
the target area, blood exudes from the poked area. Blood samples were collected into K2EDTA 
Target area for puncture 
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coated tubes; the collection tube was gently tapped to mix with K2EDTA then immediately 
stored on ice.  We collected blood samples minimum 2 weeks of interval, so as per guideline 
of National Health and Medical Research Council (NHMRC) we aimed to obtain 0.25 ml to 
0.28 ml blood from each mouse (considering average body weight 35 to 40 g; total blood 
volume 2.45 to 2.8 ml; 10% of total blood volume for every two week interval collection) 
during each blood collection period (Diehl et al., 2001; Morton DB & Seamer J, 1993). We 
observed mice for 15 minutes after blood collection, and no incidence occurred during blood 
collection.   
 
2.5.2 Blood collection by Cardiac puncture 
Mice were anaesthetised by Isoflurane inhalation (Detail of Anaesthesia procedure below) then 
blood samples were collected by cardiac puncture then euthanised due to exsanguination.  The 
blood sample was separately aliquoted for plasma and serum. We had used K2EDTA coated 
microfuge tubes for plasma sample and Serum separator tubes (BD Microtainer SST, 
Catalogue no. 365967) to separate serum. Plasma sample tubes kept on ice after blood 
collection and SST was kept at room temperature. 
 
 
2.6 Fasting blood collection 
Mice were fasted in a separate cage with new fresh puracel bedding to make sure no food 
samples or faecal samples are available in the cage during fasting. Fasting cage was identical 
to normal housing cage with all environment enrichment materials. During fasting, mice were 
allowed to drink water. Blood samples were collected by submandibular vein bleeding 
technique in K2EDTA coated 1.5 ml microfuge tubes. Immediate after fasting blood collection 
mice were transferred to their corresponding normal housing cages.   
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Study 2 
A fasting blood sample was collected from each mouse following a 6-hour fast (from 12:00 to 
18:00) for Study 2. We stacked mice to set for fasting to maintained 6 hour fasting time for an 
individual mouse. Fasting blood samples were collected during week 4 and 6 weeks of each 
diet treatment. To minimise variation between fasting and postprandial blood collection 50% 
of mice (n = 6) from each diet treatment were used for fasting blood collection and rest 50% 
mice (n = 6) for postprandial blood collection in each blood collection week.   
 
Study 3 
Mice were fasted overnight, from 20:00 to 08:00 (next day, for 12 hrs.) in fasting cages then 
we collected fasting blood samples on week 4 of each diet treatment except chow diet treatment 
as we collected on week 2.  To minimise the impact of overnight fasting we had started fasting 
at 20:00, i.e., two h after the start of the Dark Phase Cycle (18:00 to 06:00) to permit feeding 
in the 2 hrs window between 18:00 to 20:00. Mice were stacked to set for fasting to maintain 
12 hours of fasting time for an individual mouse. Mice were allowed to drink water during 
fasting.    
 
2.7 Post-prandial blood collection 
Mice were fasted then given ad libitum access to food for 45 min before blood collection. Mice 
were stacked to set for fasting then followed the same order to expose to food so that there was 
no variation of fasting time followed by feeding and postprandial blood collection time. Blood 
samples were collected in K2EDTA coated tubes by sub-mandibular vein bleeding technique 
and stored on ice.  
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Study 2 
Mice were fasted from 12:00 to 18:00 (for 6 hrs) in fasting cages then transferred into their 
normal housing cage for ad libitum accesses to food. Few feed pallets were placed on bedding 
so all mice can have easy access to food within 45 minutes. After 45 minutes of feeding, we 
collected a blood sample by submandibular vein bleeding techniques. Postprandial blood 
samples were collected on week 4 and 6 of each diet treatment. 
 
Study 3 
Mice were fasted overnight from 20:00 to 8:00 am (total 12 hrs) then fed by oral gavage (Able 
Scientific, Catalogue # ASGN7915, 16G ball-tipped curved metal gavage pipe; length 51 mm; 
ball diameter 3 mm). Food paste of 10% P control casein, control whey and Amino Acids 
supplemented casein diets were prepared by mixing grind feed samples with water (ratio Food 
and water 1:2). A total volume of 300-400 µl of food paste (10 µl g body weight as per NHMRC 
guidelines) was placed on the base of the tongue; several attempts were taken to feed total 
volume, in each attempt around 50-100 µl of feed paste was placed on the tongue using oral 
gavage needle and syringe. Mice naturally swallow the food paste delivered in this way. Each 
mouse took approximately 2-3 mins to complete feeding. Mice were anaesthetised 45 min after 
feeding by Isoflurane inhalation then blood sample collected by a cardiac puncture; mice were 
euthanised due to exsanguination. After euthanasia, tissue samples (liver, kidney, spleen, and 
brain) were collected. 
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2.8 Plasma preparation and storage 
Plasma was separated from anticoagulant coated blood sample tubes by centrifugation at 
2900 x g at 40C for 10 minutes. Light yellowish to light pinkish supernatant of plasma sample 
was separated from microfuge tube. We added a Protease Inhibitor Cocktail (catalogue no. 
P8340, Sigma Aldrich) to inhibit serine, cysteine, aspartic, and metalloproteases (Ayache et 
al., 2006). Dipeptidyl Peptidase 4 inhibitor (DPP-4, Catalogue no. DPP4-010, Abacus ALS) 
was added to ensure the stability of GLP-1(Wewer Albrechtsen et al., 2015).  Immediately 
after separation of plasma sample Protease Inhibitor Cocktail and DPP-4 inhibitors was 
added, each inhibitor was added at 1:100 ratio (i.e. 1 µl inhibitor in 100µl plasma) then mix 
thoroughly by pipetting up and down without making bubbles. Plasma samples were 
aliquoted and stored at -800C for further analysis.  
 
Study 2 
Plasma samples were prepared, aliquoted and stored on each blood collection day. Plasma 
samples were collected on week 4 and 6 of each diet treatment, in case of chow diet treatment 
we collected blood samples on week 3 of diet treatment. 
 
Study 3 
Plasma samples were prepared, aliquoted and stored on each blood collection day. Plasma 
samples were collected on week 4 of each diet treatment, except chow diet treatment, plasm 
samples were prepared in week 2.  
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2.9 Serum preparation 
At the end of the study, we euthanised mice and collected blood by cardiac puncture. A blood 
sample was collected in K2EDTA coated tube for plasma and microtainer SST, Serum 
Separator Tube (BD, Catalogue no. 365967) for serum. SST was kept at room temperature for 
2 hours then serum was separated by centrifugation at 2900 x g at 220C for 10 min. Serum 
sample on top of the gel layer in SST was collected and aliquoted in a small microfuge tube 
and stored at -800C for further analysis.  
 
Study 2 and 3  
We collected blood sample by cardiac puncture during euthanasia and separated serum 
samples. Serum samples were aliquoted and stored at -800C for further study. 
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2.10  Urine collection 
A urine sample was collected 2 hours (8 pm) after starting the dark phase. The mouse was held 
over a small plastic container, and gentle transabdominal pressure was applied over the bladder 
(Kurien, Everds & Scofield, 2004). As soon as mouse urinated, the mouse was placed back 
into its cage and urine aspirated with sterile pipette in a sterile microfuge tube. The volume of 
60 to 200 µl of urine sample was collected in this way, with minimal distress to the animal. 
Immediately after a collection urine sample was stored on ice, then preserved at -800C for 
further analysis. 
 
Study 2 
A urine sample was collected from the individual mouse on the last week of each diet treatment, 
i.e. 6th week of each diet treatment except chow diet treatment, urine samples were collected 
on 3rd week. 
 
Study 3 
The urine sample was collected from the individual mouse on the last week of each diet 
treatment, i.e. 4th week of each diet treatment except chow diet treatment, urine samples were 
collected on 2nd week. 
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2.11  Body composition  
We measured body composition at the beginning (baseline) of the study then last week of each 
dietary treatment. We measured body weight, and then body composition scanning was done 
during the light phase (6 am to 6 pm). The mouse was placed into the appropriately sized (20g 
– 100g) red tube holder based on rodent body weight.  The mouse was gently guided towards 
the end of the tube holder with the help of the tube insert provided and position the animal 
comfortably towards the end of the tube, where the animal has free access to air (Fig. 2.2), the 
tube insert was in place and secured with Velcro strap. While in the tube, animals were shortly 
exposed to a low-intensity electromagnetic field to measure fat, lean mass, free water, and total 
body water and free water. This system generates a signal that modifies the spin patterns of 
hydrogen atoms within the subject and uses an algorithm to evaluate the four components 
measured—fat mass, lean muscle mass equivalent, total body water, (Nixon et al., 2010). It 
takes approximately 2 minutes to scan one mouse. Scanned data were captured and stored for 
further analysis.  
Immediate after scanning mouse was put back into its cage. To avoid cross-contamination tube 
was cleaned with disinfectant after each scan.     
 
 
Fig. 2.2. Position of the mouse inside the scanning tube during EchoMRI scanning 
 
Studies 2 and 3 
We measured the body composition of each mouse on the last week of each diet treatment.  
 Red tube holder 
Mouse  
Tube inserts 
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2.12  FGF-21 analysis 
We used a sandwich enzyme immunoassay ELISA kit (Supplier; BioVendor, Catalogue no. 
Rd291108200R) to analyse mouse plasma FGF-21. Detail protocol comes with the kit, a brief 
overview of the procedures; we prepared reagents and standards as per instruction. Frozen mice 
plasma samples were thawed and mix thoroughly just before the assay. Samples were diluted 
ten folds (15 µl plasma in 135µl dilution buffer) in dilution buffer. Diluted samples, standards 
and control reagents were added on an antibody-coated microtiter plate. The plate was 
incubated and washed as per instruction. The absorbance of each well was determined at 630 
nm and 450 nm (after adding stop mix) using microplate reader (Tecan, Infinite M1000 pro). 
The standard curve was constructed by plotting the mean absorbance (Y) of standards against 
the known concentration (X) of standards in logarithmic scale. The measured concentration of 
FGF-21 calculated from standard curve then multiplied by x10 dilution factor to obtain an 
actual concentration of FGF-21 (pg/ml) in the sample. The serum level of FGF-21 in C57BL/6J 
mice on a standard chow diet is approximately 0.65 ± 0.2 to 1.1 ± 0.5 ng ml-1 (Morrice et al., 
2017; Rusli et al., 2016). The detection limit of FGF-21 was 40 pg ml-1. 
 
Studies 2 and 3 
We measured FGF-21 from fasting blood plasma samples of each diet treatments.  
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2.13  Gut metabolite and adipocyte-derived hormones  
The gut metabolite hormone MAGPIX system, magnetic bead-based multi-analyte panels from 
Millipore (Catalogue no. MMHMAG -44K), was used to analyse gut metabolite hormones 
(Active-Ghrelin, GLP-1and PYY) and adipocyte-derived Leptin in Study 3. The detailed 
protocol is provided with the kit. Briefly, frozen plasma samples were thawed, vortexed, and 
centrifuged at 3,000 x g for 5 min. Reagents were prepared as per instruction of kit. 96-well 
plates were prepared as per instruction (please see the layout of components in each well) 
 
Table 2.5. Reagents and materials per well of 96 wells plate for MAGPIX system 
All reagents were prepared as per instruction. Based on the number of samples, reagents and materials 
were prepared. Antibody-beads were sonicated and vortexed before aliquot. 
 
Reagents Standards wells 
(µl) 
Control Wells 
(µl) 
Background 
(µl) 
Samples 
(µl) 
Serum Matrix 10 10 10 - 
Assay Buffer - - 10 10 
Standards/Controls 10 10 - - 
Samples - - - 10 
Antibody-Beads 25 25 25 25 
Total volume 45 45 45 45 
 
The prepared plate was incubated overnight at 40C. Appropriate plate washing techniques were 
followed to save magnetic beads in each well. After following all reagents adding, incubation 
and washing procedures recommended amount of drive fluid was added on the plate. The plate 
was read on the MAGPIX with xPONENT software; it automatically measured the 
concentration of relevant gut metabolite hormones in each sample.  
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Study 3 
We have measured gut metabolite hormones of fasting and postprandial plasma samples of 
Study 3 only. Circulating level of active ghrelin in 6 months old C57BL/6J mice on a chow 
diet that fasted for 24 hours is approximately 200 pg/ml (Sun, Garcia & Smith, 2007). Also, 
circulating level of leptin, GLP-1 and PYY in fasted three months old C57BL/6J mice are 
approximately 4-6 ng/ml, 3-4 pg/ml and 300-400 pg/ml respectively (Liu et al., 2013; Martin 
et al., 2006). The detection limit of Ghreline, GLP-1, PYY and Leptin were 2.3, 13.67, 2.3 and 
23 pg ml-1 respectively.            
 
2.14  Analysis of plasma and serum metabolites 
Plasma and serum metabolites were analysed by Auto analyser AU480 (Beckman and Coulter 
Inc., Brea, California, USA) at Carbohydrate Nutrition Research lab in Charles Perkins Centre, 
University of Sydney. We analysed plasma and serum metabolites for Chapter 4 but only serum 
metabolites for study Chapter 5. Plasma and serum samples were thawed, vortexed and mix 
thoroughly before analysis. All reagents were sourced from Beckman and Coulter. Plasma 
albumin (catalogue no. OSR6102), urea (catalogue no. OSR6134), glucose (catalogue no. 
OSR6221), cholesterol (catalogue no. OSR6116), triglyceride (catalogue no. OSR60118), 
HDL (catalogue no. OSR6195) and LDL (catalogue no. OSR6196) were analysed. The 
autoanalyser was calibrated using calibration kit (catalogue no. DR0070) to analyse each 
metabolite, for HDL cholesterol (catalogue no. ODC0023) and LDL cholesterol (catalogue no. 
ODC0024) special calibration kit was used to calibrate the machine. 
 
Study 2 and 3 
We have measured plasma metabolites of each diet treatments.  
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2.15  Analysis of urine metabolites 
Auto analyser AU480 was used to analyse the amount of calcium, phosphate, glucose, 
creatinine and urea in urine. Reagents, those we used to analyse plasma and serum also used to 
analyse the urine sample. Urine calibration kit (catalogue no. DR0090) was used to calibrate 
the Auto analyser. Urine creatinine calibrator (Catalogue no. DR0091) was used to calibrate 
the autoanalyser before creatinine analysis. 
 
Studies 2 and 3 
Urine metabolites of mice on each diet treatment were measured. 
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Study 1: Food preference study 
3.1 Introduction 
Protein is generally recognised as the most satiating macronutrient (Berthoud et al., 2012) and 
consistent with this a large number of studies suggest that increased dietary protein reduces 
food intake and promotes weight loss (Gosby et al., 2014; Huang et al., 2013; Potier, Darcel & 
Tome, 2009; Westerterp-Plantenga et al., 2009). Among the macronutrients, there is a 
hierarchy of satiety efficacies. After protein, the next most satiating macronutrient is 
carbohydrate, followed by lipid (Westerterp-Plantenga et al., 2009). Dietary protein intake 
induces the release of complex signals from the gut, including short peptides and free amino 
acids that are derived by luminal digestion and act on local amino acid-sensitive receptors or 
following their uptake via intracellular metabolism to control the release of peptide hormones 
and local neuronal activity to modulate macronutrient metabolism as well as appetite and 
satiety (Journel et al., 2012). Even though the satiety-inducing effect of dietary protein is 
widely accepted, it is not clear whether different proteins have differential effects on satiety 
and food intake. Some studies have reported that some types of proteins (e.g., Whey Vs Casein; 
Beef, Chicken and Fish protein) have differential effects (Hall et al., 2003; Uhe, Collier & 
O'Dea, 1992). On the other hand, some studies have reported no differences between different 
proteins on food intake (e.g., egg albumin, casein, gelatin, soy protein, pea protein and wheat 
gluten (Lang et al., 1998).   
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In addition to the quantity of a protein consumed, the quality of a protein (referring to the 
balance of its AA composition), also appears to have an impact on food intake and protein 
metabolism. For example, some studies have reported that some mammalian species (e.g., Rat) 
rapidly detect and avoid diets that contain proteins, which are imbalanced in their amino acid 
profiles (Harper & Peters, 1989; Leung, Rogers & Harper, 1968; Sanahuja & Harper, 1963).  
 
In a previously unpublished study, in which mice were divided into high protein (33%P), 
medium protein (23%P), and low protein (13%P) diets, we observed key differences in the 
responses to casein and whey-containing diets according to these different protein levels 
(Larsson, 2014). Each of the three diet groups comprised eight mice aged 12 weeks that were 
singly housed with ad-libitum access to water and food. All mice were provided sequentially 
with (i) whey-based, (ii) casein-based (iii) whey-based and finally (iv) a control chow diet for 
a total of 41 weeks (Fig. 3.1).  
 
Fig. 3.1. Effects of whey- and casein-based diets on food intake at different %P levels 
The three groups of 8 mice, each were exposed to the same %P level (13%, 23% or 33%) for a total 
of 41 weeks during which they were switched from (i) whey to (ii) casein, then back to (iii) whey 
prior to a final control period in which they were exposed to control chow.  
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During the first period on the whey diets, food intakes for low (13%P), medium (23%P) and 
high (33%P) protein groups were surprisingly stable at 2.9 ± 0.1, 2.7 ± 0.1 and 2.8 ± 0.1 g day-
1 respectively. During the period on the casein diet, food intakes were respectively 3.6 ± 0.1, 
3.3 ± 0.1 and 3.2 ± 0.1 g day-1. During the second period on the whey diets, food intakes for 
low (13%P), medium (23%P) and high (33%P) protein groups were respectively 3.3 ± 0.1, 3.0 
± 0.1 and 3.0 ± 0.1 g day-1. Across the 41 weeks of the study, body weight increased in low 
13%P group from 31.7 ± 1.1 g (n = 8) to 40.9 ± 1 g (n = 7). When food intake was expressed 
relative to body weight, the differences in food intake between the first and second periods on 
the whey diet were reduced/nearly eliminated. For example, during the first period on the 
whey-based 13%P diet, food intake was 92.1 ± 2.6 g kg-1 and during the second period on the 
whey-based 13%P diet 81.6 ± 3.2 g kg-1  
 
Whey and casein are both considered to be high-quality proteins containing a good balance of 
amino acids, including essential amino acids (Table 3.2). Thus, the differences that were 
observed in food intake on the casein-based and whey-based diets in our unpublished study, 
particularly at low %P, are interesting and require explanation. Since the diets were 
isoenergetic (DE = 17 MJ Kg-1) with fixed carbohydrate contents (50% of DE), potential 
explanations for the variation in food intake might include taste or texture or arise from the 
detection of a difference in amino acid composition. We decided to undertake a food preference 
study to test for differences in selection between casein- and whey-based diets as %P changed. 
 
Previously, Sørensen et al. (Sorensen et al., 2008) used a food preference study in mice to test 
the impacts of multiple head-to-head comparisons of distinct % protein levels in the range 9-
48% using casein-only diets. Faced with a choice between a low (9 %P) and a high (48% P) 
protein diet, mice preferred the high 48%P diet for the first three weeks. Subsequently, the 
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preference shifted to the low 9% P diet. Faced with a choice between a low-medium (17%P) 
and a high (48%P) protein diet, mice preferred the low-medium protein diet over the high 
protein diet. Similarly, faced with a choice between a medium (23%P) and a high (48%P) 
protein diet, mice preferred the medium protein diet over the high protein diet. The study 
appeared to reveal that mice maintain a target dietary protein intake, which is easier to achieve 
at medium (17-23%P) dietary protein levels. We decided to design a food preference study for 
a different purpose: to test how the preference for different proteins changes as %P changes.   
  
Therefore, the present study aimed to determine whether there are any differences in food 
intake, food preference and body weight gain between casein- and whey-based diets 
concerning: 
(1) Total food intake at different %P levels  
(2) Food selection between casein-based and whey-based diets at different %P levels. 
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3.2 Study Design 
The study was conducted on mice model; C57BL/6J mice were used in this study. 
 
3.2.1 Animal husbandry 
We used C57BL/6J mice age between 10 to 18 months at the beginning of the study; see further 
details of animal husbandry in Chapter 2. We preferred older mice, in which intake energy is 
used for basal metabolism rather than growth. These mice were initially sourced for a different 
study, which was unable to proceed. To minimise the impact of variation in the study, we 
increased the number of mice to n =16.  
 
3.2.2 Experimental diets 
Casein and Whey diets were used in this experiment, details of diets in the General Materials 
and Methods section. Sunset yellow food colour (20 mg/Kg) was added with whey diets to 
differentiate from casein diets. To be consistent with the previous study described in the 
introduction, iso-energetic (17 MJ/kg) diets were used.   
 
3.2.3 Diet preference 
Mice were given ad libitum access to whey and casein diets that contained equal amounts of 
protein, lipid and carbohydrate, with the only difference between them being the type of protein 
they contained. Whey and casein diet had different colour and diets were separated on food 
hoper by a piece of stainless-steel food divider (Fig. 3.2). We swapped around whey and casein 
diet every week so that both diets were equally exposed to mice and treatment variations were 
minimised.     
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Fig. 3.2.  Preference between two different types of food, Casein based diet 
(White) and Whey based diet (brown) 
Mice had ad libitum accesses to both feeds. Every week feeds are swapped around to 
minimise treatment biases.  
 
3.2.4 Sequence of diets 
Mice were treated with the following sequence of diets (Table 3.1) during this study. 
Table 3.1 Sequence of diet treatments and preference (except Chow diet) 
Sixteen male mice were studied for 28 weeks. As shown below, after a period on the control chow diet, 
all mice were provided with a choice between two diets, one casein-based and the other whey-based at 
the same %P level. Similar to initial control chow diet after 10%P diet mice were provided chow diet 
only, without choice.  
 
Diet treatment Preference/ Choice Duration (weeks) 
Chow diet No choice 3 
23% Protein diet Whey Vs Casein 5 
13% Protein diet Whey Vs Casein 5 
33 % Protein diet Whey Vs Casein 5 
10% Protein diet Whey Vs Casein 5 
Chow No choice 5 
7.5% Protein diet Whey Vs Casein 5 
 
Whey diet 
Casein diet 
Food divider 
Water 
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3.3 Data collection 
3.3.1 Food intake 
Food intake (g) was measured by weighing (Weighing scale, Model no. NHB-2000 ++, Weigh 
Pty. Ltd.) the contents of the food hoppers in each cage once per week. During the food 
preference part of the study, we measured leftover whey and casein food samples separately. 
Negligible spillage of food occurred. Daily food intake was calculated based on total amount 
of food intake divided by number of days and number of mice per cage.    
 
3.3.2 Bodyweight 
Bodyweight was measured in g by manually weighing individual mice on weighing scale 
(Weighing scale, Model no. NHB-2000 ++, Weigh Pty. Ltd.) at the same time while we 
measured food intake. We measured body weekly throughout the study. 
 
3.3.3 Statistical analysis 
Statistical analysis was performed using IBM SPSS Statistics Version 24. To determine 
differences of treatments within the group and between groups analysis of variance (ANOVA) 
was performed, followed by Tukey Post-hoc analysis. All errors would be Standard Error of 
Mean (SEM) unless it was stated otherwise. We considered statistical significance if P < 0.05.  
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3.4 Results 
The diet preference study was performed on 12-18-month-old C57BL/6J male mice, who were 
caged in pairs. All 16 mice were provided with the same diet sequence. Initially, they were 
provided with a control chow diet followed by 23%P, 13%P, 33%P, ten %P, a second period 
on chow and finally, 7.5%P (Fig. 3.2). A diet preference between casein-based and whey-based 
foods at the same %P level was available during all these periods except the periods on chow.  
The %C contents of the diets that varied in %P were fixed (%lipid varied with %P). To 
investigate how variation in %P influenced food intake, we focused on overall food intake 
during the diet sequence.   
 
3.4.1 Total Food intake 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.3 The effect of % P changes in diet on food intake during the food preference study 
Food intake in the last three weeks of each dietary treatment. Except for the periods on chow, mice had 
ad libitum access to both whey- and casein-based diets. Food intake was comparable across all diets 
except for the 7.5%P option in which food intake was significantly increased concerning the 10-23%P 
options. Level of significance *p <0.05, ** p< 0.01, *** p<0.001, n = 16 mice.          
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Analysis of variance with Tukey’s post-hoc test was used to assess whether there were any 
differences in food intake during the sequence of diets using the last 3-weeks of the total 5-
week periods during which food intake had generally plateaued. Interestingly there were no 
significant differences in food intake between 10%P-33%P when compared with one another 
or with chow. In particular the food intakes per mouse were 4.1 ± 0.1 g day-1 for 23%P, 4.1 ± 
0.1 g day-1 for 13%P, 3.9 ± 0.1 g day-1 for 33%P, and 4.2 ± 0.1 g day-1 for 10%. The food 
intakes per mouse for the first and second chow periods were 4.5 ± 0.2 g day-1 and 4.0 ± 0.3 g 
day-1 respectively.  
 
On the other hand, we observed a pronounced increase in food intake on the lowest 7.5%P 
protein diet compared with other diets. When compared with the medium-range 23%P diet, for 
example, food intake on the 7.5%P was significantly increased by around 25-30% to 5.0 ± 0.2 
g day-1.    
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3.4.2 Selections of casein- and whey-based diets as %P changed in the food 
preference study  
As noted above, with the exceptions of the periods on the chow diets, mice were provided with 
a choice between two diets across all %P diets (7.5%-33%P), either bovine casein-based diets 
or bovine whey-based diets. All diets were comparable in their contents of other 
macronutrients, micronutrients and vitamins. 
 
Fig. 3.4 The effect of % P on preference for Casein or Whey-based diets 
The data represent food intakes for the last three weeks of each dietary treatment. Only food 
preference data are presented (i.e. Chow diet intake not shown on this graph) data are organised from 
high %P to low %P rather than a sequence of treatments.*p <0.05, ** p< 0.01, n = 16. 
 
Although we observed no differences in total food intake when comparing the 33%P diet to 
the 10%P diet, we observed substantial changes in preference between casein and whey as %P 
changed. At 23% protein diet treatment the casein-based diet was preferred (casein intake 3.5 
± 0.1 g day-1, whey intake 0.6 ± 0.1 g day-1; casein: whey preference was 85.1 ± 2.3%: 14.9 ± 
2.3 %).  Interestingly, as %P fell, the whey diet was noticeably preferred to the casein-diet. For 
example, for 13%P, casein intake was 2.1 ± 0.1 and whey intake was 2.0 ± 0.1 g day-1 (casein: 
0.0
1.0
2.0
3.0
4.0
5.0
6.0
33% P 23% P 13% P 10% P 7.5% P
Fo
od
 in
ta
ke
 (g
 d
ay
-1
)
Diet treatment
Whey diet (g) Casein diet (g)
** 
* 
* 
* 
s 
59 
 
whey preference, 53.0 ± 3.3%: 47.0 ± 3.3%) but at 10%P, casein was no longer preferred so 
that casein intake was 1.6 ± 0.1 g day-1 and whey intake was 2.6 ± 0.1 g day-1 (casein: whey 
preference was 37.2 ± 2.7 %: 62.8 ± 2.7%). Interestingly, as %P was lowered further to 7.5%P 
there was no clear preference between the two diets; thus, food intake on the casein diet was 
2.4 ± 0.3 g day-1 (49.3 ± 4.9 %) and on the whey diet was 2.6 ± 0.2 g day-1 (50.7 ± 4.9%).  
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3.4.3 Preference shift from casein-based diet to whey-based diet as %P changed 
in diets 
 A. 
 
B.  
 
Fig. 3.5 The effect % P on preference for casein or whey-based diets 
A. The data represent food intake on a diet over the last three weeks of each dietary treatment. 
B. The data represent food intake on a diet over the last three weeks of each dietary treatment  
* p<0.05, ** p< 0.01, *** p<0.001, n =16. 
 
As noted above, casein was the most preferred diet at 23%P, with %P fell in diet preference of 
casein dropped significantly (Fig. 3.5.A). On the other hand, whey was least preferred at 23%P, 
but the preference for whey increased significantly as %P fell in the diet (Fig. 3.5.B). At 10%P 
diet whey-based diet was most preferred. 
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3.5 Discussion 
In an unpublished study, we previously found that male C57BL/6J mice constrained to whey-
casein-whey diet sequence of fixed %P exhibited significant differences in food intake 
depending on %P and whether the diet was casein or whey-based. In particular, at the 23%P 
level food intake on the casein-based diet was 3.3 ±  0.1 g day-1 (n = 8) and on the whey-based 
diet food intake was 2.7 ± 0.1 g day-1. At 13%P level food intake increased on the casein diet 
to 3.6 ± 0.1 g day-1 but food intake was stable on the whey diet at 2.9 ± 0.1 g day-1.  
 
The experiments reported in this chapter were designed to investigate the origins of entranced 
sensitivity of %P on the casein-based as opposed to the whey-based diet. In particular, we 
designed a food preference study to investigate whether casein or whey might be preferentially 
selected at different %P levels. Thus, at all %P level tested from 33 to 7.5, the mice were 
provided with a choice of casein or whey-based diets which were otherwise identical in their 
compositions of %C, %F and micronutrients. Interestingly, we observed that total food intake 
was constant at %P fell from 33 to 10. Thus, at 23% P total food intake was 4.1 ± 0.1 g day-1, 
at 13%P total intake was 4.1 ± 0.1 g day-1 and at 10%P intake was 4.2 ± 0.1 g day-1. Thus, the 
mice were able to maintain a constant energy intake over an expanded %P range by titrating 
between two distinct protein sources, casein and whey.    
 
In this preference study, we observed mice constrained a total food intake even though %P 
dropped from 33%P to 10%P. At 23%P diet total food intake was 4.1 ± 0.1g day-1, with 
decreased % P in diet mice, maintained similar food intake. At 13%P diet total intake was 4.1 
± 0.1g day-1 and at 10%P diet total food intake was 4.2 ± 0.1g day-1. Previous studies on mice 
on casein-based diets have reported that food intake increases with decreases in dietary protein 
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as the %P value drops below around 15% (Huang et al., 2013; Solon-Biet et al., 2014). 
Although we also observed this behaviour in mice on casein-based diets, we did not observe 
this behaviour in mice on whey-based diets (see Introduction Fig. 3.1) and did not observe this 
behaviour in the casein and whey food preference study until %P dropped to 7.5.  
 
In addition to our observation that total food intake was constant at %, P fell to as low as 10; 
we observe an interesting shift in diet preference. At 23%P casein was preferred such that it 
accounted for 85.1 ± 2.3% of all food intake. As %P fell, we observed that the preference 
shifted progressively from casein to whey. At 10%P food intake of the casein-based diet was 
only 37.2 ± 2.7% with a corresponding increase in the whey-based diet to 62.8 ± 2.7%. It was 
exciting to observe that total food intake was constant even though %P dropped from 33 to 10. 
At the 7.5%P level, however, it seems that neither whey-based nor casein-based diets were able 
to cover amino acid deficiencies arising from the alternative protein source (casein or whey 
respectively). As a result, food intake increased markedly to fulfil the requirements for various 
amino acids and no preference was observed for either protein source.   
 
The twin observation of stable food intake across a broad range (33-10) %P levels and a shift 
in preference from casein to whey at low %P might be explained by a preference for specific 
amino acids that satisfy to gut and/or central amino acids sensing mechanism coupled to satiety.  
To explore this further, we estimated the amino acid content in casein and whey using the 
amino acid composition of the major protein components of bovine National Centre for 
Biotechnology Information (NCBI) database. Bovine casein consists of kappa-casein, beta-
casein, alpha S1 casein and alpha s2 casein, the molar ratio of these proteins in casein 
0.6:10.9:7.6:0.9 respectively (Ramirez-Palomino, Fernandez-Romero & Gomez-Hens, 2014). 
Bovine whey consists of beta-lactoglobulin, alpha-lactalbumin, serum albumin and other; 
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molar ratio of these protein 65:25:8:2 (Farrell et al., 2004). We had identified amino acids 
composition of all these protein fractions of casein and whey from NCBI database then 
estimated total amino acid composition. We also collected amino acid composition datasheets 
for the casein and whey protein isolates from the supplier (Fonterra, Auckland, New Zealand).  
Table 3.2.  Calculated and estimated amino acid profile of Casein protein and Whey 
Protein Isolate 
NCBI column refers to calculated AAs composition in Casein and Whey using NCBI Protein database. 
In the calculation process, we considered Casein consists of kappa-casein, beta-casein, alpha S1 casein 
and alpha s2 casein. On the other hand, Whey consists of beta-lactoglobulin, alpha-lactalbumin, serum 
albumin and others. Fonterra column represent the estimated AA   
 
 
 
 
 
Notes: *Aspartic Acid (2.6) and Asparagine (3.1) ** Glutamine (8.8) and Glutamic Acid (10.5) 
            * Aspartic Acid (3.5) and Asparagine (6.6) ** Glutamine (5.2) and Glutamic Acid (8.0) 
Green highlighted rows show AA higher in casein and Blue highlighted rows show AA higher in 
whey protein isolate 
 
The amino acid profiles of casein and whey protein mixtures in Table 3.2 demonstrates some 
striking differences in amino acid composition. Casein has more L-Arg, L-Glu + L-Gln, L-His, 
Amino&Acids& NCBI&[M&wt.]&(g/100&g)& Fonterra&(g/100&g)&Alanine& 3.3# 2.8#Arginine& 3.0# 3.5#Aspartic&acid&(Asp&+&Asn)& 5.7*# 6.6#Cysteine& 0.5# 0.7#Glutamic&acid&(Glu&+&Gln)& 19.1**# 20.8#Glycine& 1.8# 1.8#Histidine& 2.6# 2.6#Isoleucine& 5.3# 4.9#Leucine& 11.0# 8.8#Lysine& 7.0# 7.4#Methionine& 3.3# 2.8#Phenylalanine& 4.9# 4.8#Proline& 10.6# 10.2#Serine& 5.9# 5.4#Threonine& 3.5# 4.0#Tryptophan& 1.0# 1.2#Tyrosine& 4.3# 5.4#Valine& 7.1# 6.2#&
Amino&Acids& NCBI&[M&wt.]&(g/100&g)& Fonterra&(g/100&g)&Alanine& 8.6$ 5.1$Arginine& 1.7$ 2.2$Aspartic&acid&(Asp&+&Asn)& 10.1*$ 10.3$Cysteine& 4.5$ 2.6$Glutamic&acid&(Glu&+&Gln)& 13.2**$ 17.3$Glycine& 3.3$ 1.7$Histidine& 1.7$ 1.7$Isoleucine& 5.5$ 6.5$Leucine& 14.0$ 10.3$Lysine& 8.9$ 9.4$Methionine& 2.5$ 2.2$Phenylalanine& 2.9$ 3.0$Proline& 3.7$ 5.8$Serine& 4.6$ 4.6$Threonine& 5.3$ 6.7$Tryptophan& 1.5$ 1.7$Tyrosine& 2.5$ 3.1$Valine& 5.3$ 5.8$&
Casein Protein (Acid Casein) Whey Protein  
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L-Met, L-Phe, L-Pro, L-Ser, L-Tyr and L-Val compare to whey protein. On the other hand, 
whey contains more L-Ala, L-Asp + L-Asn, L-Cys, L-Leu, L-Lys, L-Thr and L-Trp.  Casein 
and whey are comparable in their contents of L-Ile and perhaps L-Ser.   
 
To assess how the intakes of individual amino acids changed as %P changed, and selection 
changed between casein and whey.  We calculated the intakes of individual amino acids based 
on amino acids composition in 100g protein. In particular, we were interested in determining 
whether the intakes of any individual amino acids were stable as %P fell, and whey was 
preferred over casein.    
A. 
 
B. 
 
C. 
 
D. 
 
Fig. 3.6 Intakes of casein enriched individual AAs as %P, and food preference changed 
Intakes of AAs were calculated from food intakes of the last three weeks of 7.5%P, 10%P, 13%P and 
23%P diet.   
Note:     Refers to intake of Amino acid,   refers to If mice would have eaten a similar amount of 
Casein diet only then amino acid intake,      If mouse would have eaten a similar amount of Whey 
diet only then amino acid intake.  
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A. 
 
 B.  
 
C. 
 
 D. 
 
Fig. 3.7 Intakes of whey-enriched individual AAs as %P and food preference changed  
Intakes of AAs were calculated from food intakes of the last three weeks of 7.5%P, 10%P, 13%P 
and 23%P diet.  
Note:     Refers to intake of Amino acid,    refers to If mice would have eaten a similar amount of Casein 
diet only then amino acid intake,        refers to if the mouse would have eaten a similar amount of Whey diet 
only then amino acid intake.  
 
From the data provided in Fig. 3.5 it is clear that the intakes of AAs enriched in casein changed 
markedly as %P changed, and the shift in food preference occurred. On the other hand, from 
Fig. 3.6, we have seen some of the amino acids, specially L-Cys, L-Leu, L-Thr, L-Trp intakes 
during food preference study were consistent.  
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3.6 Conclusions 
In this food preference study we observed the protein leverage effect (Gosby et al., 2011; 
Simpson & Raubenheimer, 2005; Sorensen et al., 2008), in which low dietary protein 
concentrations drive enhanced total energy intake but only the lowest %P value tested i,e. 7.5%, 
well below that previously described for mice on casein diets, i.e., around 15% (Huang et al., 
2013; Solon-Biet et al., 2014; Sorensen et al., 2008). Instead, under conditions in which mice 
were provided with a choice between either a casein-based diet or a whey-based diet food 
intake remain constant. In achieving as %P fell, we observed a noticeable shift in preference 
from casein to whey. These results suggest that mice can obtain their minimum amino acid 
requirements at a significantly lower total %P level when two complementary protein sources 
are available. Amino acids enriched in whey including L-Cys, L-Trp, L-Ala, L-Thr, L-Lys 
were prioritised over amino acids in casein including L-Arg, L-Gl +L-Gln, L-His, L-Met, L-
Phe, L-Pro, L-Ser, L-Tyr and L-Val.   
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Study 2: Were the results of the 
casein-whey food preference study 
affected by changes in Lipid or 
Carbohydrate content? 
4.1 Introduction 
In chapter 3 “Food Preference Study” we investigated the impact on food intake of changes in 
% protein content (%P) as male C57BL/6J mice selected between foods that were based on 
either bovine casein or whey as their protein sources. We found that at a control protein level 
(23%P) wild-type adult male mice preferred a casein-based diet to a whey-based diet (Fig. 3.4). 
Total intake was 4.1 ± 0.1 g day-1, of which 85.1 ± 2.3% was obtained from the casein-based 
diet and the remaining 14.9 ± 2.3% was obtained from the whey-based diet. Interestingly, 
however, as %P was lowered to 13 and then 10 (with corresponding increases in fat content; 
carbohydrate concentration was constant at 50% of digestible energy, i.e., DE) the preference 
shifted towards the whey-based diet with no change in total energy intake. Thus, on the 10%P 
diet, total intake remained at 4.2 ± 0.1 g day-1 of which only 37.2 ± 2.7% was obtained from 
the casein-based diet and 62.8 ± 2.7% was obtained from the whey-based diet.  
As noted in the General Introduction (pp 8), satiety is affected differently by different 
macronutrients such that protein is more satiating than carbohydrate or lipid (Westerterp-
Plantenga et al., 2009). Recent studies suggest that mice target a protein to carbohydrate ratio 
of around 1: 2.5 (Huang et al., 2013; Sorensen et al., 2008). We, therefore, decided to 
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investigate whether fixing either dietary carbohydrate or dietary fat might affect food 
preference as %P changed in the food intake study. Accordingly, we repeated the food 
preference study under two distinct conditions in which either (1) carbohydrate content was 
held constant at 50% of total energy (as in the study described in Chapter 3) or (2) fat was held 
constant at 27% of total energy. For the 23%P control diet, %C was 50 and %F was 27%. At 
the 10%P level, however, %C was fixed at 50 and %F was allowed to increase to 40 in the first 
arm of the study, whereas %F was fixed at 27 and %C was allowed to increase to 63 in the 
second arm of the study. 
 
FGF 21 is a systemic peptide hormone that is synthesised in the liver (Nishimura et al., 2000) 
and coordinates multiorgan energy homeostasis especially for glucose and lipids (Fisher & 
Maratos-Flier, 2016; Woo et al., 2013). FGF-21 is widely considered to be induced by fasting 
(Inagaki et al., 2007) but is also elevated in other contexts including overfeeding, or ingestion 
of ketogenic or high carbohydrate diets (Badman et al., 2007; Potthoff et al., 2009; Solon-Biet 
et al., 2016). Nutritional geometry analysis showed that plasma FGF-21 levels correlate 
positively with carbohydrate intake but is not correlated with the fat intake (Solon-Biet et al., 
2016).   
 
FGF 21 is also recognised as a key endocrine signal of protein restriction (De Sousa-Coelho et 
al., 2013; Laeger et al., 2014; Morrison & Laeger, 2015). Thus reduced protein intake robustly 
increased plasma FGF-21 levels in male C57BL/6J mice (Solon-Biet et al., 2016) suggesting a 
negative relationship between dietary protein and plasma FGF21 levels. Consistent with this 
finding, human studies revealed that exposure to reduced dietary % P levels for four days 
increased plasma FGF-21 levels (Gosby et al., 2016). In the experiments described in this 
Chapter, we decided to investigate the impact of decreased % P on food intake and food 
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preference according to whether carbohydrate or fat was fixed and to correlate these findings 
with attendant changes in plasma FGF-21 levels.  
 
Therefore, the aims of the present study were: 
1. to determine whether there was a difference in the casein: whey food preference 
responses to changes in %P dependent on whether either carbohydrate (50%) or fat 
(27%) were held constant;  
2.  To determine whether there was a difference in the FGF-21 between %C fixed group 
and %F fixed in casein: whey preference responses to changes in %P.  
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4.2 Study design 
4.2.1 Animal husbandry 
C57BL/6J male mice, six months of age were divided into four groups; each group was 
composed of 12 mice. Mice were given ad libitum access to casein protein-based and whey 
protein-based diets that contained identical levels of protein.  Further details of the animal 
husbandry are provided in Chapter 2, General Materials and Methods section. During Chow 
diet treatment, there was no preference. A power analysis was done based on body weight and 
expected energy intake to achieve statistical power of 0.8 with Alpha 0.05.   
Details of mice allocation and feeding sequences are in Table 4.1. 
  
Group 1 (Food preference study – %C content fixed) 
Following an initial three-week chow control period (period 1), mice in this group were studied 
in six sequential periods of six weeks each (periods 2-7) for a total study period of 36 weeks. 
During periods 2-6, the mice were supplied with a choice of two diets with identical %P levels, 
which were either casein-based or whey-based (constant Carbohydrate, 50% DE). In periods 
2-6, the %P levels were selected as follows: 23, 13, 10, 7.5, and 23. Note that as %P fell, %F 
rose. In period seven the mice were returned to normal chow (with no preference allowed).  
 
Group 2 (Food preference study – %F fixed)  
Following an initial three-week chow control period (period 1), mice in this group were studied 
in six sequential periods of six weeks each (periods 2-7) for a total study period of 36 weeks. 
During periods 2-6, the mice were supplied with a choice of two diets with identical %P levels, 
which were either casein-based or whey-based (constant Lipid, 27% DE). In periods 2-6, the 
%P levels were selected as follows: 23, 13, 10, 7.5, and 23. Note that as %P fell, %C rose. In 
period seven the mice returned to control chow diet, no preference allowed.  
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Table 4.1: Sequence of diet treatments and preference (except Chow diet) 
Twenty-four male C57BL/6J mice were studied for 36 weeks. As shown below after a period on the 
control chow diet mice in %C fixed group and % F fixed group were provided with a choice between 
two diets, one casein-based and the other whey-based at the same %P level. 
 
Treatment diet Period Group-1 %C fixed Group-2 %F fixed 
Chow  1 No choice No choice 
23% Protein 2 Whey Vs Casein  Whey Vs Casein  
13% Protein 3 Whey Vs Casein  Whey Vs Casein  
10% Protein 4 Whey Vs Casein  Whey Vs Casein  
7.5% Protein 5 Whey Vs Casein  Whey Vs Casein  
23% Protein 6 Whey Vs Casein  Whey Vs Casein  
Chow 7 No choice  No choice 
 
4.2.2 Diet design 
In this study 14 custom made diets were used, all these diets were modified AIN93G diet, and 
high energy density (17 MJ/kg) commercial supplier Speciality Feeds, Glen Forrest, Western 
Australia, Australia manufactured in dry, pelleted form. One set of diets (Group-1) contained 
a fixed percentage of the total energy of carbohydrate (50% of DE) and the second set of diets 
(Group-2) contained a fixed percentage of lipid (27% of DE). The Detailed compositions of all 
diets are provided in Chapter 2, General Materials and Methods. 
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4.2.3 Sequence of events 
The following sequence of events was followed during the study described in chapter 4 
Arrival Week  
• Mice were acclimatised, and health examined  
• Mice were distributed in cages (2 mice/ cage), All mice were seven weeks 
old   
   
Aging for 
 Four months  
One week 
 
• All mice had ad libitum access to standard Chow diet and water.  
• Monitored two times per week  
• Corncob bedding used for four months 
• Mice bedding changed to puracel bedding (suitable for feeding study). 
   
Study week 
 1- 3  
 
• All groups were on standard chow diet. 
• Bodyweight and food intake measured weekly 
• Fasting blood collected in week 1.  
• Postprandial blood and urine samples collected in week 3.  
• Body composition analysed by EchoMRI during week 3.  
   
Study week 
4 - 9  
 
• All groups were on 23%P diet. 
• Bodyweight and food intake measured weekly 
• Whey diet and casein diet swapped around each week for Group1 and 2  
• Fasting and postprandial blood collected during week 7 and 9.   
• Urine samples collected during week 9.  
• Body composition analysed by EchoMRI during 9th week 
   
Study week 
10 - 15 
 
• All groups were on 13%P diet.  
• Bodyweight and food intake measured weekly 
• Whey diet and casein diet swapped around each week for Group 1 and 2. 
• Fasting and postprandial blood collected during week 13 and 15  
• Urine samples collected during week 15  
• Body composition analysed by EchoMRI during week 15. 
   
Study week 
16 - 21  
 
• All groups were on 10% P diet.  
• Bodyweight and food intake measured weekly 
• Whey diet and casein diet swapped around each week for Group 1 and 2 
• Fasting and postprandial blood collected during week 19 and 21.  
• Urine samples collected during week 21.  
• Body composition analysed by EchoMRI during week 21. 
 
(Continue) 
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Study week 
22– 27 
 
• All groups on 7.5%P diet. 
• Bodyweight and food intake measured weekly 
• Whey diet and casein diet swapped around each week for Group 1 and 2 
• Fasting and postprandial blood collected during week 25 and 27.   
• Urine samples collected during week 27.  
• Body composition analysed by EchoMRI during week 27.  
   
Study week 
28th – 33rd  
 
• All groups were on 23%P diet. 
• Whey diet and casein diet swapped around each week 
• Bodyweight and food intake measured weekly 
• Fasting and postprandial blood collected on week 31 and 33.  
• Urine samples collected on week 33.  
• Body composition analysed by EchoMRI during week 33. 
   
Study week 
34 –36  
 
• All groups were on a chow diet. 
• Whey diet and casein diet swapped around each week for Group 1 and 2 
• Bodyweight and food intake measured weekly. 
• Fasting blood collected during week 36.  
• Urine samples collected during week 36.  
• Body composition analysed by EchoMRI during week 36. 
   
Final week  
• All mice were anaesthetised by Isoflurane inhalation then euthanised by 
withdrawing blood by cardiac puncture. 
• Serum and plasma samples were prepared from  
• Tissue samples (kidney, liver, spleen and brain) were collected for 
histopathology and further analysis 
 
Fig. 4.1 Flow diagram showing the sequence of events that were followed during the study  
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4.3 Data collection 
4.3.1 Food intake 
Food intake was measured by weighing the contents of the food hoppers each week. While 
weighing food, negligible spillage of food was confirmed by visual examination on the bottom 
of cages. To minimise feeding variation during food preference steps (period 2 to 6) for Group-
1 and Group-2, the same strategy was followed as described in Fig.3.2, Chapter 3.    
 
4.3.2 Body Weight 
Bodyweight (g) was measured weekly throughout the study at the same time that food intake 
was measured.  
 
4.3.3 Body composition  
Body composition was assessed using EchoMRI 900 at the beginning of the experiment, then 
at the end of each diet treatment, i.e. week 3, 9, 15, 21, 27, 33 and 36. Details of EchoMRI in 
Chapter 2, General Materials and Methods section. 
 
4.3.4 Fasting blood collection 
Mice were fasted from 12:00 to 18:00 (6 hours) for fasting blood sample collection. The blood 
sample was collected by the submandibular vein bleeding technique. Detail of fasting blood 
collection techniques in Chapter 2, General Materials and Methods. We collected fasting blood 
from 50% mice (n = 6) of each diet treatment group and postprandial blood from rest 50% of 
mice (n = 6) of the group. We kept this pattern consistent with obtaining a homogenous sample. 
Blood samples were collected on week 1, 7, 9, 13,15, 19, 21, 25, 27, 31, 33 and 36. Plasma 
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samples were isolated by centrifugation for 10 minutes at 1000x g and stored at -800C until 
further analysis.  
 
4.3.5 Postprandial blood collection 
Mice were fasted for 12:00 to 18:00 (6 hours) in fasting cage, then given ad libitum access to 
food for 45 min. For easy access to feed, we left some feed on the bedding so both mice can 
have easy access to feed. After 45 minutes exposed to feed postprandial blood samples were 
collected on week 3, 7, 9, 13,15, 19, 21, 25, 27, 31, 33, 36. Blood samples were collected in 
K2EDTA coated 1.5 ml microfuge tubes.  
 
4.3.6 Plasma preparation 
The plasma sample was processed from blood samples with an anticoagulant. Protease 
inhibitor cocktail and Dipeptidyl peptidase-4 inhibitor were added into plasma samples then 
aliquoted and stored at -800C for further analysis. Details of plasma preparation in Chapter 2. 
 
4.3.7 Serum preparation 
Serum samples were prepared from blood samples collected by cardiac puncture during 
euthanasia. The blood sample was collected in SST for serum, detail of serum preparation in 
Chapter 2, General Materials and Methods. Collected serum was aliquoted and stored at -800C 
for further analysis.    
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4.3.8 FGF-21 analysis 
We used a sandwich enzyme immunoassay ELISA kit (Supplier; BioVendor, Catalogue no. 
Rd291108200R) to analyse mouse plasma FGF-21. Details of FGF-21 analysis in Chapter 2.  
 
4.3.9 Plasma metabolites 
Plasma metabolites (albumin, urea, glucose, cholesterol, triglyceride, HDL and LDL) were 
analysed using auto analyser AU 480 at Carbohydrate Nutrition Research lab, Charles Perkins 
Centre, University of Sydney. Detail of the procedure in Chapter 2. 
 
4.3.10 Statistical analysis  
Statistical analysis was performed using IBM SPSS Statistics Version 24. To determine the 
difference of treatment within the group and between-group analysis of variance (ANOVA) 
was performed, followed by Tukey Post-hoc analysis. All errors would be Standard Error of 
Mean (SEM) unless it was stated otherwise. We considered statistical significance if P <0.05.  
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4.4 Results 
The diet preference study described in Chapter-3 was repeated on two groups of 6 months of 
age C57BL/6J male mice. In Group-1 carbohydrate was fixed as for the study described in 
Chapter-3. In Group-2 fat was fixed to allow us to investigate whether either of the other two 
macronutrients modulated the total food intake and preference of diet. Mice from both groups 
were caged in pairs. There were two additional differences between the studies described in 
this Chapter and that described in Chapter-3: (i) the maximum %P was 23% and (ii) the 
sequence of diets was as follows: control chow, 23% P, 13%P, 10%P, 7.5%P, 23%P, and 
finally control chow. At all %P levels, two different diets, either casein-based or whey-based, 
were available except the periods in which the mice were constrained to control chow. Thus, 
the mice were able to select between either casein-based or whey-based diets as %P varied 
from 7.5% to 23%.   
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4.4.1 Total Food intake 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.2 Effect of %P on food intake in Group-1 (%C-fixed) and Group-2 (%F-fixed)  
Food intakes are shown for the last three weeks of 6 weeks on Chow, 23%P_1, 13%P, 10%, 7.5%P, 2nd time 
23%P and finally 2nd-time chow diet Preference of whey diet in Group-1 and Group-2. *p <0.05, ** p < 
0.01, *** p <0.001. Each group was composed of 12 mice. 
 
We compared food intakes between Group-1 and Group-2 according to the different %P values. 
No statistically significant differences were found between the two groups on each diet. 
However, within each group, some notable differences were observed according to %P. In 
particular, total food intake increased in both groups as %P fell to 10% and below and similar 
results were observed in both groups, i.e., the results were not affected by whether %C or %F 
was fixed in the diet. Also, as %P fell below 23%, and consistent with the findings reported in 
Chapter-3, there was a noticeable increase in preference for whey relative to casein. Thus, in 
Group-1, when %P changed from 23% to 13% whey intake increased from 0.8 ± 0.03 g day-1 
to 1.3 ± 0.1 g day-1.  Similarly, in Group-2, when %P changed from 23% to 13% whey intake 
increased from 0.9 ± 0.05 g day-1 to 1.4 ± 0.1 g day-1. Total food intake dropped with increased 
%P, in group-1 at 2nd time 23%P diet treatment food intake dropped to 2.9 ± 0.1 g day-1. Similar 
results obtained in group-2, total food intake decreased to 3.1 ± 0.1 g day-1.    
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4.4.2 Selections of casein- and whey-based diets as %P changed in Group-1 and 
Group-2 
 
A. 
  
 
B. 
  
Fig. 4.3 Effect of %P on whey and casein intakes in Group-1 (%C-fixed) and -2 (%F-fixed) 
Food intakes are shown for the last three weeks of 6 weeks on 23%P, 13%P, 10%, 7.5%P and 2nd time 23%P 
diet when both groups of mice were in preference study. 
A. Preference of whey diet in Group-1 and Group-2.  
B. Preference of casein diet in Group-1 and Group-2.  
* p < 0.05, ** p < 0.01, *** p < 0.001; each group was composed of 12 mice. 
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ANOVA was used to identify differences in food preference between groups. No differences 
in food preferences observed between groups.  However, we have seen similar patterns of 
preference of casein and whey as %P dropped in both groups.  In Group-1 (%C fixed) at 23% 
protein diet treatment, the casein-based diet was preferred casein intake was 1.9 ± 0.1 g day-1 
and whey intake were 0.8 ± 0.1 g day-1; casein: whey preference was 69.3 ± 2.6%: 30.7 ± 0.7%.  
Interestingly, as %P fell, the whey diet was noticeably preferred to the casein-diet. For 
example, for the 13%P whey intake was 1.3 ± 0.1 g day-1 preference increased to 43.5 ± 1.6%. 
Similar to our previous study at 7.5%P diets, there was no clear preference between two diets. 
Interestingly, in this study, we observed during 2nd time, 23%P the preference of casein diet 
increased to 78.6 ± 1.3 %.   
In Group-2 (%F fixed), we have seen a similar scenario that we observed in Group-1. These 
findings are consistent with our previous findings in chapter 3. Mice preferred casein to whey 
when they are on a high to medium protein diet with decreased %P in diet preference of casein 
substantially decrease, and preference of whey in the diet increased regardless of %C fixed or 
%F fixed 
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4.4.3 FGF-21 in Group-1 and Group-2 
Plasma FGF-21 of mice from diet Group-1 and Group-2 were measured from fasting plasma 
samples collected during each diet treatment. Mice of both diet groups fasted from 12:00 to 
18:00 (6 hrs.). Plasma FGF-21 was measured by sandwich enzyme immunoassay.  
 
 
Fig.4.4 The effect of %P on fasting plasma FGF-21 (ng/ml) in Group-1 (%C fixed) and 
Group-2 (%F fixed)  
The data represent fasting plasma FGF-21 in Group-1 and Group-2 mice on chow, 23%P, 13%P, 10%, 
7.5%P, 2nd time 23%P and final chow diet. Data compared within same diet group. * p <0.05, ** p < 
0.01, *** p <0.001, each group was composed of 12 mice. 
 
No differences of fasting plasma FGF-21 observed between the two groups. However, within 
each group, some differences in fasting plasma FGF-21 were observed according to %P. At 
the 1st control chow and 1st  23%P diet treatment plasma FGF-21 in group-1 (%C fixed) was 
0.7 ± 0.1 ng ml-1  and  0.9 ± 0.1 ng ml-1  respectively, with decreased %P in diet fasting plasma 
FGF-21 increased, at 10%P it was 3.8 ± 0.5 ng ml-1.  Similar results were observed in Group-2 
with gradual decrease %P in diet fasting FGF-21 increased proportionately; we observed 
identical patterns in both group which reflect %C and %F in the diet does not affect fasting 
plasma FGF-21.   
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4.4.4 Bodyweight in Group-1 and Group-2   
 
Fig. 4.5 The effect of %P in diet on Bodyweight (g) of mice in Group-1 (%C fixed) 
and Group-2 (%F fixed)  
Bodyweight (g) is shown for the last three weeks of 6 weeks in Group-1 and Group-2 mice 
on chow, 23%P, 13%P, 10%, 7.5%P, 2nd time 23%P and final chow diet. * p < 0.05, ** p < 
0.01, ***p < 0.001. Each group was composed of 12 mice. 
 
No difference in body weight was observed between Group-1 and Group-2 (p = 0.999) on each 
diet during a sequence of diet treatments. However, we observed some differences in body 
weight gain within groups. In Group-1 (%C fixed) mice gained significant body weight 
compared to 23%P diet, with decreased %P in diet and time mice gained body weight 
gradually.  
In Group-2, I observed a similar pattern of body weight gain.  
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4.4.5 Body composition 
Body composition analysis, i.e. % fat mass, %lean mass and total water, provide a better view 
of the actual impact of diet on body weight gain or loss. EchoMRI was done to analyse body 
composition. 
    
4.4.6 Fat mass in Group-1 and Group-2 
On the last week of each diet, body composition of each mice from Group-1 and Group-2 were 
measured using EchoMRI. 
 
Fig. 4.6 The effect of %P in diet on Fat mass (%) of mice in Group-1 (%C fixed) and 
Group-2 (%F fixed)  
The data represent fat mass (%) in Group-1 and Group-2 mice on chow, 23%P, 13%P, 10%, 7.5%P, 
2nd time 23%P and final chow diet. Changes of % fat mass were compared in food preference group 
only. * p < 0.05, ** p < 0.01, *** p < 0.001. Each group was composed of 12 mice. 
 
Although we did not observe a variation of % fat mass between the two groups of mice on each 
diet, we observed substantial changes in fat mass (%) within groups that increased with time.  
In Group-1(%C fixed) at 23%P_1 body composition consists of 10.7 ± 1.4 % of fat mass, with 
decreased %P in diet food intake and body weight, increased which lead to increase in fat mass 
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(%). We observed a similar pattern in mice of Group-2 (%F fixed), even though there were no 
differences between groups but in Group-2 progression of changing % fat mass was slower.  
 
4.4.7 Lean Mass (%) in Group-1 and Group-2 
 
Fig. 4.7 The effect of chow diet and %P in diet on Lean mass (%) of mice in Group-
1 (%C fixed) and Group-2 (%F fixed) 
The data represent lean mass (%) in Group-1 and Group-2 mice on chow, 23%P, 13%P, 10%, 7.5%P, 
2nd time 23%P and final chow diet. Changes of % lean mass were compared in food preference group 
only. * p < 0.05. Each group was composed of 12 mice. 
 
Similar to body weight (g) and % fat mass, we did not find differences in % lean mass between 
two groups of mice on each diet. Compare to body weight and % fat mass we found % lean 
mass were more stable, at low %P, i.e. 10% and 7.5%P level even though food intake, body 
weight, and % fat mass increased but % lean mass did not increase. 
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4.5 Discussion 
In the food preference study described in Chapter-3, we found that male C57BL/6J mice 
preferred casein-based to whey-based diets when %P in the diets was 23%-33%. However, the 
preference for the casein-based diet declined as %P decreased and at 13%P and 10%P whey-
based diets were preferred (see Fig. 3.4).  Interestingly, as %P fell from 23%P to 10%, P food 
intake remained constant and only increased in response to 7.5%P suggesting that neither 
casein-based nor whey-based diets nor an adjusted mix at the two were sufficient to provide 
the required amino acids. To investigate whether either of the other two macronutrients might 
modulate the effect of %P on food preference the study was repeated in the experiments  
described in Chapter 4 under two distinct conditions in which either  (1) carbohydrate content 
was held constant at 50% of total energy (as in the study described in Chapter 3) or (2) fat was 
held constant at 27% of total energy. The results from these two variants of the casein-based 
and whey-based diets are described in this Chapter. Similar to the study described in Chapter 
3, we found that mice preferred casein-based diets over whey-based diets at 23%P, but as %P 
fell the preference shifted to whey, and this effect was similar regardless of whether % C fixed 
or %F was fixed (Fig.4.2)      
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4.5.1 Total food intake 
In the study described in the current chapter there were no differences in total food intake in 
either food preference group (i.e. %C fixed or %F fixed) until %P fell below 13% (Fig. 4.2). 
Thus, at 23%P, food intake in %C fixed diet was 2.8 ± 0.2 g day-1 and with %F fixed was 2.8 
± 0.2 g day-1, noting that at 23%P, the two diets were identical (i.e. %C was 50% and %F was 
27%). When %P was lowered to 13%P food intake increased to 3.1 ± 0.1 g day-1 (%C fixed, 
%F = 37) and to 2.9 ± 0.1 g day-1 (%F fixed, %C = 60). None of the differences in food intake 
between the various diet groups at 13%P was statistically significant.  
 
In a previous mouse study, it was found that food intake increased with decreases in %P to less 
than 17%P, and the effect was amplified when the P:C ratio fell to 17:64 and below (Huang et 
al., 2013).  Increases in food intake as %P fell below 15% were also observed in a human study 
(Gosby et al., 2011). In the current food preference study, I did not observe differences of food 
intake even at 13%P, and the results were similar in the %C fixed (P:C ratio 13:50) and %F 
fixed (P:C ratio 13:60) groups. Although food intake increased further as %P was lowered to 
10, unlike the study described in Chapter 3 in which food intake remained constant (see Fig. 
3.4), no differences were observed between the %C fixed (P: C ratio 10:50) and %F fixed (P: 
C ratio 10:63) groups.  
 
4.5.2 Impact of %P on the selection of casein and whey-based diets  
Similar changes in food preference were observed as %P fell from 23 to 10 in the current study 
(Fig 4.3) as had been observed in the study reported in Chapter 3 (Fig. 3.4). Thus at 23%P, 
mice in both the C fixed and F fixed diet groups preferred casein to whey, casein preferences 
were 69.3 ± 0.7 % and 66.3 ± 1.3 % respectively. On the other hand, as %P fell to 13%P, the 
preference for casein decreased to 54.1± 1.1 % with the C fixed and 52.9 ± 4.3 % with the F 
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fixed groups. However, as seen in the previous study (Fig. 3.5) no clear preference of neither 
casein nor whey was observed as %P in diets were low as 7.5.  
 
As I mentioned earlier, we had seen significant differences of food intake in this study as % P 
in diet fell 10 and below, but in our earlier study described in Chapter 3 we had seen a consistent 
amount of food intake as %P in diet fell to 10.  In both studies, I observed a shift of diet 
preference from casein to whey-based diet as %P fell but interestingly in the previous study I 
observed a substantial decrease of casein-based diet intake which was not observed in this 
current study. For example, at 10% P diet in previous study casein: whey preference was 37.2 
± 2.7%: 62.8 ± 2.7% on the other hand in this study at 10%P casein: whey preference was 52.9 
± 1.2%: 47.1 ± 1.2%. Of course, the question is why we observed these minor differences in 
preference shift; one explanation may be age differences of mice. In study Chapter 3, mice 
were between 12 to 18 months of age at the beginning of the experiment; on the other hand, at 
the beginning of this study, mice were six months of age. Studies suggest elderly mice maintain 
a consistent amount of food intake (Akimoto et al., 2012; Solon-Biet et al., 2014). So, provided 
an option of casein and whey-based diet had helped mice to maintain consistent food intake as 
well as meet up amino acid requirements by switching preference from casein to whey as %P 
in the diet reduced. But at 7.5%P diet neither casein nor whey nor the mixture of casein and 
whey-based diet meet up amino acids requirement, so mice increased food intake regardless of 
choice to meet up amino acids requirement.   
 
In a previously reported human study, no differences in appetite were observed when subjects 
were provided with a choice among 25%P whey or soy or casein diet. On the other hand,  when 
subjects were given either 10%P  whey or casein or soy diet food intake was significantly low 
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with 10%P whey compared to other two 10%P diets (Veldhorst et al., 2009). These results, 
specially whey and casein diet intake differences, are similar to those observed by us (Fig. 3.1). 
    
4.5.3 Implication of the switch in food preference 
In this study, we observed a shift in preference from casein to whey as %P fell. Twin 
observations in this study justify our ideas  
I. mice can obtain their minimum amino acid requirements at a significantly lower 
total %P level when two complementary protein sources are available  
II. Amino acids enriched in whey can satisfy central amino acids sensing mechanism 
coupled to satiety more effectively then amino acids enriched in casein.  
It is generally accepted that protein-induced satiety than carbohydrate or fat (Bensaid et al., 
2002; Bertenshaw, Lluch & Yeomans, 2008; Marmonier, Chapelot & Louis-Sylvestre, 2000). 
And it is also widely accepted that some nutrient-sensing mechanisms, not the ingested energy 
content of the diet, are involved with this satiety effect. Dietary protein exhibit satiety through 
few mechanisms such as  
I.  Direct effects of amino acids concentration in the brain,  
II. Peripheral or gut-derived metabolite hormones and neural signals and  
III. other endocrine signals like FGF-21 (Morrison & Laeger, 2015).  
In a previous human study, Hall et al. reported whey protein (48g protein, total DE 1700 kJ) 
preload was more effective in decreasing food intake than a similar amount isoenergetic casein 
preload. Also, whey protein was more effective in increasing the serum levels of satiety 
hormones CCK and GLP-1 (by around 60 – 70%). Whey protein was more effective in 
increasing plasma AA levels (by around 25 - 30%) and persisted for more than 3h (Hall et al., 
2003). Furthermore, in another human study, a 12% increase in food intake was reported when 
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10%P diet was selected over 15%P diet, but interestingly no differences of food intake 
observed when %P increased from 15 to 25 (Gosby et al., 2011). 
 
Rats preferred control diet over amino acid imbalanced diet, but when amino acid imbalance 
was adjusted, the diets were preferable over amino acid imbalanced diets (Leung, Rogers & 
Harper, 1968). All these findings are consistent with my ideas that rodent and human 
consistently maintain minimum amino acid requirement either by increasing food intake when 
%P in diets are low or by shifting preference when requiring amino acids complementary diets 
are available.  
 
4.5.4 FGF-21 
As noted in the introduction to Chapter 4  FGF-21 is recognised as an endocrine signal of 
protein restriction (De Sousa-Coelho et al., 2013; Laeger et al., 2014; Morrison & Laeger, 
2015). In the current study, I investigated whether the reduction of %P with either casein or 
whey-based diets affected fasting plasma FGF-21 levels. As expected, I observed an increase 
in plasma FGF-21 levels as %P fell from 23 to 10 and then 7.5 (Fig 4.4). Thus, at 23%P, the 
plasma FGF-21 was 0.9 ± 0.1 ng ml-1 in the %C fixed group, and a similar result was obtained 
in the %F fixed group. At 10%P FGF-21 was 3.8 ± 0.5 ng ml-1(%C fixed group) with a similar 
result in %F fixed group. Our findings are comparable to those of Solon-Biet et al., who 
reported that plasma FGF-21 significantly increased with reduced protein in diets (Solon-Biet 
et al., 2016). Reduced AA supply to the liver increased hepatic FGF-21 production, which acts 
on the hypothalamus and perhaps other CNS centres to increase both food intake and energy 
expenditure (Morrison & Laeger, 2015).  
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4.5.5 Body weight 
I also investigated the impact of the food preference studies on body weight (Fig 4.5); no 
differences were observed between the %C fixed and %F fixed groups. However, some 
differences in body weight were observed within groups in particular as %P fell food intake 
increased, and mice gained body weight. Similar observations were reported in previous 
studies, in which mice on lowest P:C ratio diets gained excess weight. (Huang et al., 2013; 
Solon-Biet et al., 2014). It is generally accepted that weight gain occurs when food intake 
exceeds energy expenditure leading to progressive increases in body weight and adiposity. In 
the current study, all experimental diets (except the control chow diet) were on high energy 
diets, i.e. energy content was 17 MJ Kg-1. As mice were switched from moderate energy, i.e. 
14 MJ Kg-1 control chow diets to high energy diets, mice progressively gained weight 
regardless of %P (Sorensen et al., 2008). So, the overall weight gains observed in the food 
preference studies described in this chapter appears to have arisen from the higher digestible 
energies of the diets used.  
 
4.5.6 Body composition 
To determine whether the observed preference shift from casein to whey as %P fell had any 
impact on body composition, EchoMRI was performed. No significant differences were 
observed between the groups (see Fig. 4.6 and Fig. 4.7). Previously Huang et al. reported that 
body fat was negatively correlated with dietary protein content, i.e. as %P in the diet decreased 
will increase food intake and increase % body fat (Huang et al., 2013).  
 
We did not observe % lean mass differences between the %C fixed Vs %F fixed groups. 
However, lean mass at 2nd 23%P diet in %C fixed group (i.e. %P and %F varied) was 
significantly high compared to 1st time 23%P. Whey protein isolate-based 20%P high-fat diet 
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increased lean mass compare to similar %P high fat casein-based diet (McAllan et al., 2014), 
which reflects % lean mass influenced by types of proteins. In this current study, mice were 
provided a choice of two protein-based diets so lean mass difference is were not evident until 
2nd 23%P diet in the %C group, but we observed %C fixed or %F fixed had no impact on lean 
mass.       
 
4.6 Conclusion: 
In this food preference study, we established  
1. Food preference is real, i.e. mice switch preference of diet to obtain their minimum 
amino acid requirements regardless of %C content or %F content in the diet.  
2. At high %P level whey diet are less preferable to casein-based diet as %P dropped whey 
diet become preferable due to amino acid composition in whey.   
3. Plasma FGF-21 is not affected by %C content or %F content in the diet; rather, it is 
more affected by %P in the diet.   
4. Mice on a high energy diet constantly gained weight as %P drops and increase food 
intake regardless of %C content of %F content in the diet,  
5. Body fat mass associated with %P in diet, food intake, energy content and body weight 
gain. 
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Study 3: Identification of candidate 
amino acids in the regulation of food 
intake: roles of amino acids enriched 
in whey 
5.1 Introduction 
As noted above, dietary protein suppresses food intake and the experiments described in this 
thesis indicate that some proteins, e.g., whey, are more effective than others, e.g., casein in 
suppressing appetite. Although casein and whey are both high-quality proteins, the results of 
pervious study (Larsson, 2014) as well as previous chapters demonstrate that they have 
different effects on food intake and thus appetite control particularly at low %P values, from 
the 10-13%P levels. Thus, I observed that whey is more potent than casein in regulating food 
intake at low %P and may arise from differences in amino acid composition between the two 
proteins. A human study found that compared to casein, whey decreased food intake and 
hunger by increasing the postprandial or fasting serum levels of satiety hormones CCK by 60% 
and GLP-1 by 65% (Hall et al., 2003). Following protein digestion liberated free amino acids 
are sensed peripherally and centrally to regulate appetite (Fromentin et al., 2012; Morrison & 
Laeger, 2015; Potier, Darcel & Tome, 2009).  
 
Gut metabolite hormones play significant roles in appetite control, energy metabolism and the 
regulation of food intake. Concerning food intake, gut metabolite hormones may be either: 
i. Orexigenic (appetite-stimulating), ghrelin has been the only known appetite-
stimulating hormone; or  
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ii. Anorexigenic (appetite suppressing), of which GLP-1, PYY, CCK, GIP are well-
known examples. All four are released in response to ingested food and promote 
satiety hormone.   
Appetite is regulated by suppressing the levels of orexigenic hormones or by modulating the 
levels of satiety hormones or both. As discussed in the General Introduction (Chapter 1) 
primary secretion sites of satiety hormones are the Duodenum/Jejunum for CCK and GIP and 
Ileum/colon for GLP-1 and PYY.  
 
Small intestinal endocrine cells are an important source of satiety hormones, including 
Cholecystokinin (CCK), Glucagon-like peptide-1 (GLP-1), and Peptide-tyrosine-tyrosine 
(PYY) (D'Alessio, 2008). CCK is released from I-cells, and GLP-1 and PYY are released from 
L-cells (D'Alessio, 2008; Gibbs, Young & Smith, 1973; Habib et al., 2013). Tissue-dependent 
regulators of appetite have also been identified. These include the peptide hormone leptin, 
which is released from adipocytes and acts to suppress appetite in the context of a replete 
triacylglycerol store (Ronveaux, Tome & Raybould, 2015) and, more recently, FGF21, which 
is produced in liver, pancreas and white adipose tissue (Angelin, Larsson & Rudling, 2012), 
and whose role in appetite control is under active investigation. Indeed recent work indicates 
FGF-21 controls dietary protein intake in male mice (Larson et al., 2019).  
 
In the analysis described in Chapter 3 and from the amino acid compositions of whey and 
casein, I identified as many as eight amino acids that are present at higher levels in whey 
compared to casein. These eight amino acids, either individually or in combination, may be 
responsible for the greater appetite suppressing the effect of whey. In attempting to prioritise 
amino acids for further testing, we noted that three amino acids, L-Cys, L-Thr, L-Trp had intake 
levels that were relatively stable upon the transition from the preference for casein at 23%P to 
the preference for whey at 10%P (Fig. 3.7). On this basis, I identified L-Cys, L-Thr and L-Trp 
as candidates for further testing in the experiments described in the present chapter.  If one or 
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more of these amino acids are responsible for appetite suppression at low %P, adjustment of 
the casein-based diets at low %P by addition of L-Cys, L-Thr or L-Trp  (e.g, at the level present 
in 23%P whey)  I expected that food intake levels would be comparable to those observed for 
the whey-based diets.  
 
L-Cys 
L-Cys is a conditionally essential amino acid when the dietary L-Met supply is limited 
(McGavigan et al., 2015). It is a precursor for biologically active molecules such as glutathione, 
taurine and hydrogen sulphide (H2S). Recently oral administration of L-Cys was reported to 
reduce food intake in both rats, mice and humans, acting to reduce gastric emptying and to 
suppress plasma ghrelin levels (McGavigan et al., 2015). In human experiments, it suppressed 
hunger (McGavigan et al., 2015).      
 
L-Thr 
L-Thr is an essential amino acid for protein synthesis. An early study demonstrated that rats 
prefer a protein-free diet over L-Thr deficient amino acid-imbalanced diet. When the L-Thr 
content was corrected, the rats preferred the balanced diet over L-Thr deficient diet (Leung, 
Rogers & Harper, 1968). More recently, rats were reported stopped feeding prematurely upon 
exposure to an imbalanced diet in which L-Thr was deficient (Koehnle, Stephens & Gietzen, 
2004). The Anterior Piriform Cortex (APC) of the brain detects  L-Thr deficiency via a 
mechanism in which uncharged tRNA activates the protein kinase General Control Non-
derepressing 2 (GCN2) to block general protein synthesis via enhanced phosphorylation of 
Eukaryotic Initiation Factor (Maurin et al., 2005).   
 
L-Trp 
L-Trp is an essential amino acid that is generally considered to be among the least available of 
all proteinogenic amino acids (Gostner et al., 2019). A study in humans reported that L-Trp 
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suppresses food intake by stimulating the release of key satiety hormones, including CCK and 
GLP-1 (Meyer-Gerspach et al., 2016). In rats, intraduodenal administration of L-Trp increases 
plasma GLP-1 and insulin levels, and the CaSR which is activated by aromatic amino acids 
including L-Trp and L-Phe (Conigrave, Mun & Lok, 2007), plays a role in mediating the effect 
of L-Trp on GLP-1 secretion (Zapata et al., 2018). 
 
Since the hormonal basis of appetite control that underlies food preference is not well 
understood, I measured the serum levels of a subset of appetite modulating and satiety 
hormones in the current study. 
 
The aims of the study presented in this chapter were  
1. To test whether supplementing 10%P casein-based diet with one of the individual 
amino acids, L-Cys, L-Thr or L-Trp to the level found in the 23% P whey-based diet 
would suppress food intake. 
2. To test the effect supplementing the casein-based 10% diet with one of these individual 
amino acids on the serum levels of ghrelin, PYY, Leptin and FGF-21  
3. To test whether supplementation of 10%P casein-based foods with all three amino acids 
(L-Cys, L-Trp and L-Thr) to emulate the amino acid contents in the 23% P whey-based 
diet might suppress food intake or affect the serum level of ghrelin, PYY, leptin and 
FGF-21. 
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5.2 Study design 
C57BL/6J male mice, six months of age were divided into six groups; each group was 
composed of 8 mice. We also considered body weight, % fat mass and % lean mass distribution 
of mice into comparable groups. A power analysis was done based on body weight and 
expected energy intake to achieve statistical power of 0.8 with Alpha 0.05. Details of mice 
allocation and feeding sequences are provided in Table 5.2. 
 
All mice groups were studied in three distinct periods in the following order: 
(1) Initial control chow diet (2-weeks) 
(2) Standard whey-based 23% P diet (one group) and standard casein-based 23% P diet 
(five groups) for 4-weeks 
(3) Standard whey-based 10% P diet (one group); Standard casein-based 10% P diet (one 
group), and Casein-based, 10% P, supplemented with the following amino acids 
L-Cys (one group), L-Thr (one group), L-Trp (one group) and L-Cys + L-Thr + L-Trp 
(one group) for 4-weeks  
 
Group-1 (Whey)  
As described for Group-1 but in which only the whey-based diet was available in each test 
period according to the %P sequence described above. 
 
Group-2 (Casein) 
During period 3, the mice were supplied with a standard Casein-based diet available in each 
test period according to the %P sequence described above.  
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Group-3 (Casein + L-Cys) 
 
During period 3, the mice were supplied with a casein-based diet that was supplemented with 
L-Cys to achieve a final content of 0.62 g/100g (i.e., the L-Cys content in a 23%P whey-based 
diet 0.62 g/100g, Table 5.1).  
 
Group-4 (Casein + L-Thr) 
During period 3, the mice were supplied with a casein-based diet that was supplemented with 
L-Thr to achieve a final content of 1.6 g/100g (i.e., the L-Thr content in a 23%P whey-based 
1.6 g/100g, Table 5.1).  
 
Group-5 (Casein + L-Trp)  
During period 3, the mice were supplied with a 10%P casein-based diet that was supplemented 
with L-Trp to achieve a final content of 0.37 g/100g (i.e., the L-Trp content in a 23%P whey-
based diet0.37g/100g, Table 5.1).  
 
Group-6 (Casein + L-Cys + L-Trp + L-Thr)  
During period 3, the mice were supplied with a Casein based diet that was supplemented with 
L-Cys, L-Thr and L-Trp in a combination to achieve final content as stated for Groups 3-5 
above (Table 5.1). 
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5.2.1 Diet Design 
All diets were modifications of AIN-93G. They were Iso-energetic with digestible energy (DE) 
of 14MJ/Kg. %F was fixed at 27% of DE. We measured AA contents in whey protein isolates, 
casein and control chow diet.  
 
Key differences in diet design compared to diets used in study Chapter 3 and 4 were as follows: 
• An Energy Content of 14 MJ/Kg instead of 17 MJ/Kg was used so that there was no 
change in energy content in the transition from standard chow to the casein- or whey-
based diets.  
• The diets were no longer supplemented with L-Met because adequate levels of L-Met 
were present in all test diets. Previously all diets were supplemented with L-Met 
(3g/kg). In the lowest protein diet proposed (10%P) the L-Met contents were 0.28% 
(casein-based) and 0.22% (whey-based). As per Miller et al. 2005, 0.15% L-Met is 
sufficient to support normal growth, development and, in particular, to prevent rectal 
prolapse and early death in mice aged six months or older (Miller et al., 2005).  
• To test whether the switch in preference from casein to whey at low %P was due to 
the relatively high levels in whey of three individual amino acids, L-Trp, L-Thr, or L-
Cys we supplemented the low 10%P casein diet with each of these amino acids 
individually (Groups 3-5) and also in combination (Group 6). We were not aware of 
any adverse effects arising from the supplementation of mouse diets with these three 
amino acids. 
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Table 5.1. Calculation of AAs composition based on measured AAs in Whey and Casein 
in different 10% Protein diets 
Note. #, ## and ### Refer to L-Cys, L-Thr and L-Trp respectively that were supplemented to make 
the equal amount available at 23% whey diet. 
  
  
Amino 
Acids 
Group-1* 
Whey 
(g/100g) 
Group-3 
 Casein + L-
Cys 
(g/100g) 
Group-4 
Casein + L-
Thr 
(g/100g) 
Group-5 
Casein + L-
Trp  
(g/100g) 
Group-6 
Casein +L-
Cys +L-Thr 
+ L-Trp 
(g/100g) 
Group 2 
Casein 
(g/100g) 
L-Ala 0.5 0.27 0.24 0.28 0.21 0.29 
L-Arg 0.2 0.35 0.31 0.36 0.27 0.37 
L-Asp + 
L-Asn 
1.0 0.60 0.54 0.63 0.47 0.65 
L-Cys 0.3 0.62# 0.04 0.04 0.62# 0.04 
L-Glu +  
L-Gln 
1.7 1.93 1.73 2.0 1.51 2.06 
L-Gly 0.2 0.17 0.15 0.18 0.13 0.18 
L-His 0.2 0.26 0.23 0.27 0.20 0.27 
L-Ile 0.7 0.46 0.41 0.48 0.36 0.49 
L-Leu 1.1 0.84 0.75 0.87 0.66 0.89 
L-Lys 0.9 0.70 0.62 0.72 0.54 0.74 
L-Met 0.2 0.26 0.23 0.27 0.20 0.28 
L-Phe 0.3 0.46 0.41 0.47 0.36 0.49 
L-Pro 0.6 0.96 0.86 1.0 0.75 1.02 
L-Ser 0.5 0.52 0.46 0.54 0.41 0.55 
L-Thr 0.7 0.39 1.61## 0.40 1.61## 0.41 
L-Trp 0.2 0.08 0.31 0.37 ### 0.37 ### 0.09 
L-Tyr 0.3 0.48 0.42 0.5 0.38 0.52 
L-Val 0.6 0.61 0.53 0.65 0.48 0.65 
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5.2.2 Group distribution and diet treatment sequences 
Table 5.2. Mice group distribution and diet treatment sequence 
Forty-eight male C57BL/6J mice were distributed in six groups, eight mice per group (n = 8) allocation 
and feeding sequences. Mice in all Six groups followed a standardised pattern from week 1 to week ten 
concerning control periods and %P in the diets.  
 
Protein 
(% DE) 
Group 1 
 
Group-2 
(Week) 
Group-3 
(Week) 
Group-4 
(Week) 
Group-5 
(Week) 
Group-6 
(Week) 
Chow 1st & 2nd 1st & 2nd 1st & 2nd 1st & 2nd 1st & 2nd 1st & 2nd 
23% P 
3rd – 6th 
23% 
Whey 
3rd – 6th 
23% Casein 
3rd – 6th 
23% Casein 
3rd – 6th 
23% Casein 
3rd – 6th 
23% Casein 
3rd – 6th 
23% Casein 
10% P 
 
7th-10th 
(10% 
Whey) 
7th-10th 
Casein 
7th-10th 
(Casein + L-Cys) 
7th-10th 
(Casein 
+ L-Thr) 
7th-10th 
(Casein + 
L-Trp) 
7th-10th 
(Casein + L-
Trp, L-Thr, 
L-Cys) 
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5.2.3 Sequence of events 
The following sequence of events was followed during the study described in Chapter 5 
Arrival Week  
• Mice were acclimatised, and their health was examined and confirmed.  
• Mice were distributed in cages (2 mice/ cage), All mice were seven weeks old   
   
Aging for 
 Four months  
 
 
• All mice had ad libitum access to standard Chow diet and water.  
• Monitored two times per week  
• Corncob bedding used for four months 
• Mice bedding changed to puracel bedding (suitable for feeding study). 
• The body measured and body composition analysed by EchoMRI 
• Organised diet treatment group based on body weight, % lean mass and % fat 
mass 
   
Week 1 - 2   
• All groups on standard chow diet treatment. 
• Bodyweight and food intake measured weekly 
• Fasting blood collected in 2nd week.  
• Body composition analysed by EchoMRI during 2nd week 
• Urine and faecal sample were collected during 2nd week  
   
Week 3 - 6   
• All groups except whey control (group 1) were on 23% casein diet  
• The whey group was on 23% whey diet  
• Bodyweight and food intake measured weekly 
• Fasting blood collected during week 6.   
• Faecal samples and urine samples collected during week 6.  
• Body composition analysed by EchoMRI during week 6. 
   
Week 7 – 10 
 
• All diet groups were on relevant 10% protein diet treatment.  
• Bodyweight and food intake measured weekly 
• Fasting blood collected during week 10  
• Faecal samples and urine samples were collected during week 10. 
• Body composition analysed by EchoMRI during week 10. 
• Postprandial blood collected by cardiac puncture during the euthanasia 
• Tissue samples were collected  
Fig. 5.1 Flow diagram showing the sequence of events that were followed during the study  
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5.3 Data collection 
Food intake, body weight 
Food intake and body weight were measured weekly as described for the previous study in 
Chapter 3 and 4. Details of the method used to quantify food intake and body weight are 
described in Chapter 2, General Materials and Methods.  
 
5.3.1 Body composition  
Body composition was assessed using EchoMRI 900 at the beginning of the experiment and 
then at the end of each diet treatment, i.e., weeks 2, 6 and 10.  
 
5.3.2 Fasting blood collection 
Mice were fasted overnight from 20:00 to 08:00 the next day (12 hrs). Fasting blood samples 
were collected from the submandibular vein. Details of the fasting blood collection technique 
are provided in Chapter 2.   
 
5.3.3 Postprandial blood collection 
Mice were fasted overnight from 20:00 to 08:00 the next day (12 hrs) then fed by oral gavage.  
Blood samples were collected 45 minutes later. Postprandial blood samples were collected only 
during 10%P diet treatment when all groups of mice were on relevant amino acid supplemented 
diets including casein control and whey control groups. Details of postprandial blood collection 
are provided in Chapter 2.  
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5.3.4 Plasma preparation 
Plasma samples were processed from blood samples following treatment with an anticoagulant. 
Details of plasma preparation are provided in Chapter 2. Protease Inhibitor Cocktail (Supplier: 
Sigma Aldrich) and DPP-4 (Supplier: Millipore) were added immediately after plasma 
separation then aliquoted and stored at -800C for further analysis. Detail of plasma preparation 
is provided in Chapter 2.    
 
5.3.5 Urine sample collection 
Urine samples were collected during the final week of each diet treatment, i.e. in weeks 2, 6 
and 10. Details of the urine collection are provided in Chapter 2. 
 
5.3.6 FGF-21 analysis 
FGF-21 levels were measured in samples of fasting plasma. Details of FGF-21 analysis in 
Chapter 2.  
 
5.3.7 Gut metabolite and adipocyte hormone analysis 
Gut metabolite hormones, including an active form of Ghrelin, Leptin and PYY were measured 
from fasting and postprandial plasma samples using the MagPix multiplexing system 
(Supplier: Merck Millipore, Australia). The procedure is described in detail in Chapter 2. We 
did not include Plasma GLP-1 due to inconsistency of the levels measured in both whey and 
casein control groups.   
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5.3.8 Urine metabolites 
Urine metabolites (Calcium, creatinine, glucose, phosphate and urea) were analysed using Auto 
analyser AU 480 at the Carbohydrate Nutrition Research lab, Charles Perkins Centre, 
University of Sydney. Details of the procedure are provided in Chapter 2. 
 
5.3.9 Statistical analysis  
Statistical analysis was performed using IBM SPSS Statistics Version 24. To determine 
differences between treatment within and between groups analysis of variance (ANOVA) was 
performed, followed by Tukey Post-hoc analysis. All errors would be Standard Error of Mean 
(SEM) unless it was stated otherwise. We considered statistical significance if P <0.05.  
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5.4 Results 
The study was designed to test whether supplementation of casein-based diets at low %P (10-
13) with selected L-amino acids that are enriched in whey might suppress food intake and thus 
emulate the behaviour of whey at low %P.   The study was performed on 48 six-month-old 
C57BL/6J male mice, who were caged in pairs. The mice were divided into six groups of 8 
mice each. The groups were; 1) Whey, 2) Casein, 3) Casein + L-Cys, 4) Casein + L-Thr, 5) 
Casein + L-Trp and 6) Casein + L-Cys +L-Thr + L-Trp.  
 
All mice received the same %P sequence. Initially, they were provided with control chow for 
two weeks followed by control 23%P diets for four weeks (five groups, i.e. groups 2 to 6 
received casein and one group, i.e., Group-1 received whey) and finally 10%P for four weeks.  
During the 10%P diet treatment, Group 1 received 10% whey; Group 2 received 10% casein 
and groups 3-6 received casein diets supplemented with L-amino acids as required. All diets 
were moderate energy (14 MJ/Kg) with %F fixed (27% of DE). The studies described in 
Chapters 3 and 4 investigated the differences between casein and whey in the regulation of 
appetite. In the study described in this chapter, I investigated the efficacy of the individual 
amino acids L-Cys, L-Thr or L-Trp in suppressing food intake on a background of casein 
10%P. Casein alone and whey alone at both 23%P and 10%P were used as controls. To 
investigate how variations in diets influenced food intake we focused on overall food intake, 
body weight, body composition as determined by Echo MRI, and performed analyse on the 
plasma levels of key gut metabolite hormones (ghrelin and PYY), the adipocyte generated 
peptide hormone leptin and the hepatocyte-generated peptide hormone FGF-21 as well as 
several key nutrients and metabolites (including triglycerides, total cholesterol, HDL, LDL, 
albumin and urea).    
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5.4.1 Baseline body weight and body composition 
To minimise variations between groups, 6-month-old male C57BL/6J mice were allocated to 
one of 6 groups based on body weight (g), fat mass (%) and lean mass (%).   
 
 
Fig. 5.2 Baseline body composition and body weight (g) in all diet groups 
Baseline body composition (% Fat mass, % Lean mass) and body weight (g) were measured at the 
start of the experiment (Week 0). EchoMRI was used to determine % fat mass and % lean mass (n = 
8 mice per group). Mouse groups are numbered 1- 6 as shown in table 5.1 
 
To confirm the absence of significant variations between groups at baseline, I analysed body 
weight and also body composition by EchoMRI. Bodyweight varied between groups from 33.6 
± 1.0 to 34.0 ± 0.6 g.  Fat mass between groups varied from 5.2 ± 0.6 to 5.5 ± 0.7% and lean 
mass varied between groups from 26.6 ± 0.3 to 27.3 ± 0.6 %. There were no statistically 
significant differences in baseline body weight, % fat mass or % lean mass between the 
different diet groups. 
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5.4.2 Total food intake 
The last two weeks of food intake data for each diet were used to calculate daily food intakes 
for each group.  
 
 
Fig. 5.3 Food intakes on the 23%P and 10%P diets for the different diet groups  
At 10%P, the casein-based diet was supplemented with individual amino acids L-Cys, L-Thr or L-
Trp to mimic the effect of whey-based diet. The data represent the final 2-week period for each diet 
treatment for groups 1-5. During the 23%P diet period Groups 2-5 received the casein-only diet and 
group 1 received whey. At 10%P, Group 2 continued to receive the casein-only diet. Groups 3-5, 
however, received casein-based diets supplemented with L-Cys, L-Thr or L-Trp respectively to the 
levels found in 23%P whey. * p <0.05, each group was composed of 8 mice. 
 
During the 23%P diet treatment period, I did not observe any significant differences in food 
intake between the groups. However, at 10%P, I observed that food intakes on the control 
casein diet were significantly higher compared to the control whey diet as observed previously 
(Fig. 3.1). In particular, food intake on the casein-based diet was around 10% higher at (4.0 ± 
0.1 g day-1; n = 8) when compared to the whey-based diet (3.6 ± 0.1 g day-1; n = 8; p < 0.05). 
We next tested the effects of supplementing the 10% casein diet with individual amino acids 
L-Cys, L-Thr or L-Trp to the levels found in 23%P whey. Food intake in mice on the casein 
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diet that was supplemented in the L-Cys (3.6 ± 0.1 g day-1; n = 8) significantly lower compared 
to control casein (p < 0.05). However, food intake on the L-Cys supplemented casein diet was 
significantly reduced compared to either L-Thr (4.1 ± 0.1 g day-1; n =8) or L-Trp (4.1 ± 0.1 g 
day-1; n =8) supplemented casein. In addition, unlike control casein, L-Cys was not 
significantly different from control Whey.  
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5.4.3 The impact of different diets on the gut and adipocyte-derived appetite 
modulating hormones 
I next investigated the impact of the various diets at 10%P on gut metabolite hormone levels 
in plasma prepared from fasting or 45 min postprandial blood samples. A Magnetic Bead Panel 
(MAP) multiplex assay was used to measure the plasma levels of the following hormones 
Active Ghrelin, PYY and Leptin.  
 
5.4.3.1 Active Ghrelin 
Ghrelin is an appetite hormone; there is two most abundant form of ghrelin, i.e. acylated ghrelin 
and des-acyl ghrelin. I have measured active ghrelin corresponding primarily the 3-Ser 
octanoylated form. Active ghrelin was measured from fasting and postprandial plasma samples 
of mice 10%P diets.  
 
Fig. 5.4 The effects of various diets (all 10%P) on fasting and postprandial plasma 
ghrelin levels  
For the collection of fasting samples, mice fasted overnight from 20:00 to 08:00. For the collection 
of postprandial samples, overnight fasted mice were fed by oral gavage at 08:00 and blood samples 
were collected after 45 min. Each group was composed of 8 mice. 
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We did not observe differences in either fasting or postprandial plasma ghrelin levels in mice 
on the different diets at 10%P. In particular, no differences were observed between casein or 
whey or between casein alone and casein supplemented with L-Cys, L-Thr or L-Trp.  However,  
45 min after feeding mice on all diets exhibited a marked suppression of plasma ghrelin levels 
(Fig. 5.4). In mice receiving the control 10%P casein diet the fasting plasma ghrelin level was 
345 ± 53 pg mL-1 (n = 8) and the postprandial plasma ghrelin level was 60 ± 40 pg mL-1 (n = 
8). Similar results were observed in mice receiving the other 10%P diets.            
 
5.4.3.2  PYY 
PYY is a satiety hormone. To observe the effects of different diets on satiety hormone PYY 
was measured only from fasting and postprandial plasma samples of mice on 10%P diet. 
 
 
Fig. 5.5 The effects of various diets (all 10%P) on fasting and postprandial plasma PYY 
For the collection of fasting samples, mice fasted overnight from 20:00 to 08:00. For the collection 
of postprandial samples, overnight fasted mice were fed by oral gavage at 08:00 and blood samples 
were collected after 45 min. Each group was composed of 8 mice.  * p <0.05 
 
I next investigated whether there were differences between any of diets concerning for fasting 
and postprandial levels of PYY. At 10%P, the fasting plasma PYY level in mice on the control 
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casein diet was (264 ± 6 pg mL-1; n = 8) and was significantly lower in mice on the whey diet 
(138 ± 39 pg mL-1; n = 8).  No differences in the fasting plasma PYY level were observed 
within or between the other diet groups. Similarly, no differences were observed in 
postprandial plasma PYY levels, and feeding did not affect the plasma PYY level, at least at 
the time point chosen for collecting blood (45 min).   
 
GLP-1 
Circulating level of fasting GLP-1 in C57BL/6J mice approximately 3-5 pg/ml. Fasting and 
postprandial GLP-1 data are not presented because we observed considerable inconsistency as 
well as very low concentrations.  
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5.4.4 Leptin 
Leptin is an adipocyte-derived peptide hormone that relatively modulates appetite. An 
increased level of fat stores positively promotes its levels. Leptin also plays an important role 
in energy homeostasis. 
I next investigated the impacts of low protein (10%P) diets including whey, casein and casein 
supplemented with one of the three individual amino acids L-Cys, L-Thr or L-Trp on fasting 
and postprandial plasma levels of leptin.  
 
 
Fig. 5.6 The effects of various diets (all 10%P) on fasting and postprandial plasma 
Leptin levels 
For the collection of fasting samples, mice fasted overnight from 20:00 to 08:00. For the collection 
of postprandial samples, overnight fasted mice were fed by oral gavage at 08:00 and blood samples 
were collected after 45 min. Each group was composed of 8 mice. 
 
No significant differences in fasting or postprandial plasma leptin levels were observed 
between the various diet groups (Fig. 5.6). 
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5.4.5 FGF-21 
FGF-21 is a peptide hormone that plays significant roles in multiorgan energy homeostasis and 
is synthesised primarily in the liver.  Recent studies reported that FGF-21 is a biomarker of 
protein restriction diets (De Sousa-Coelho et al., 2013; Laeger et al., 2014; Solon-Biet et al., 
2016). I focussed on fasting plasma FGF-21 levels since the time-dependent relationship 
between feeding, and FGF-21 levels are not well understood. In the final week of all diet 
treatments, mice fasted overnight as described previously, and blood samples were collected 
at 08:00 the following day and processed. The plasma samples obtained were analysed for 
FGF-21.   
 
Fig. 5.7 The effects of various diets on fasting plasma FGF-21 levels  
Mice were fasted overnight 20:00 to 08:00 for 12 hours; then fasting blood samples were collected. 
Fasting blood was collected in the final week (4th week) of the 23%P and 10%P diet treatments. Each 
group was composed of 8 mice. *p <0.05, ** p <0.001 
 
ANOVA was used to compare the fasting plasma FGF-21 among different diet groups. At 
10%P, a significant 2-3-fold increase in plasma FGF-21 levels was observed in mice on the 
control casein diet compared with the whey diet (Fig. 5.7).  Also, supplementation of the 10%P 
casein-based diet with L-Cys suppressed the plasma FGF-21 level by around 60% (p <0.001), 
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to a level comparable to that seen in mice on the 10%P whey diet and 23%P casein and whey 
diets. At 10%P, supplementation of the casein diet with either L-Thr or L-Trp had no significant 
effects on the plasma FGF-21 level (Fig. 5.7; p = 0.155 and p = 0.564). 
 
 
5.4.6 Casein supplemented with combined L-Cys, L-Thr and L-Trp 
I next investigated the impact of low protein (10%P) casein diet supplemented with all three 
candidate amino acids L-Cys, L-Thr and L-Trp on food intake and fasting plasma FGF-21 
levels.    
A. 
 
B. 
 
Fig. 5.8 The effect of the combination of L-Cys, L-Thr and L-Trp on food intake and 
fasting plasma FGF-21 levels 
A. At 10%P, the casein-based diet was supplemented with all three amino acids L-Cys, L-Thr 
and L-Trp. The data represent the final 2-week period for each diet treatment for Groups 2 
and 6. During the 23%P diet period, Groups 2 and 6 received the casein-only diet. 
B. Mice were fasted overnight 20:00 to 08:00 for 12 hours; then fasting blood samples were 
collected. Fasting blood was collected in the final week of the 23%P and 10%P diet 
treatment. Each group composed of 8 mice. ** p <0.001 
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Surprisingly, under the conditions of the experiment with 4 week diet treatment periods I did 
not observe significant differences in food intake at 10%P between control casein and casein 
supplemented with all three candidate amino acids, of L-Cys, L-Thr and L-Trp at the levels 
found in 23%P whey (Fig. 5.8.A). However, I did observe significant differences in fasting 
plasma FGF-21 levels raising the possibility that a drop in FGF-21 level might precede a drop-
in food intake and that food intake was persistently elevated by the addition of L-Thr and L-
Trp to L-Cys supplemented casein. (Fig. 5.8.B).   
 
5.4.7 Serum metabolites 
The measurement of several key nutrients and metabolites in fasting plasma albumin, urea, 
calcium, phosphate, triglycerides, total cholesterol, HDL-C, LDL-C and LDH (Appendix, 
Table 7.1) did not reveal any significant differences among mouse groups on the different diets. 
 
5.4.8 Urine metabolites 
In addition to serum metabolites, I also analysed several key urine metabolites including 
calcium, creatinine, phosphate, urea and glucose (Appendix, Table 7.2). No significant 
differences were observed among mouse groups on different diets.  
 
5.4.9 Body composition: 
On the final week of each diets treatments, body compositions were analysed. No significant 
differences were observed among mouse groups on different diets. 
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5.5 Discussion 
In the experiments described in Chapter 3 and Chapter 4, I found that male C57BL/6J mice 
preferred casein to a whey-based diet at high %P, but as %P fell to 13 or 10 the mice preferred 
whey to casein regardless of %C or %F content. I hypothesised that amino acids enriched in 
whey and relatively deficient in casein might play a role in this preference shift. The analysis 
of amino acid intake described in Chapter 3 identified as many as eight amino acids that are 
relatively enriched in whey when compared to casein. The intakes of L-Cys, L-Trp, L-Thr were 
particularly stable as %P fell, and the food preference switched to whey (Fig. 3.7). I, therefore, 
hypothesised that L-Cys, L-Thr and/or L-Trp might play roles as key determinants of food 
intake, acting to suppress food intake at high %P levels and to disinhibit food intake as their 
levels fell at low %P. To justify the hypothesis, I supplemented 10% casein-based diets with 
the individual amino acids L-Cys, L-Thr or L-Trp at their levels in 23%P whey to test whether 
one or more of these amino acids might suppress food intake to the levels seen with 23% P 
casein or whey or 10%P whey. A total of 6 groups of mice were studied. After an initial period 
on control chow of two weeks, all groups received control 23%P diets for four weeks (five 
groups, i.e. groups 2 to 6 received casein and one group, i.e. Group-1 received whey). Finally, 
all groups received 10%P diets for a further four weeks. Group 1 received 10% whey; Group 
2 received 10% casein and Groups 3-5 received 10%P casein supplemented with L-Cys, L-Thr 
or L-Trp respectively. At 10%P Group 6 received casein supplemented with combined L-Cys, 
L-Thr and L-Trp. At the beginning of the study, all mice groups had comparable body weights 
(g) and % lean mass and %fat mass (Fig. 5.2). 
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5.5.1 Total food intake 
In this study, I confirmed that at the 10%P level, food intake is reduced on whey relative to 
casein and I extended the study to test the hypothesis that three amino acids, L-Cys, L-Thr or 
L-Trp either alone or in combination might lower food intake on the casein diet. At 10%P, 
supplementation of the casein diet with L-Cys but not L-Thr or L-Trp reduced food intake 
significantly compared to the control 10%P casein diet. Indeed, food intake on casein (10%P) 
restored upon supplementation with L-Cys to a level that was not significantly different from 
that observed for 23%P casein, 23%P whey or 10%P Whey. These findings justify the 
hypothesis that there are minimum intake targets for various amino acids and that L-Cys is 
limiting in casein but not in whey. The results also suggest that L-Cys couples to a molecular 
mechanism for the suppression of food intake. Various studies have reported that L-Cys or an 
L-Cys-rich diet suppresses food intake in rodents and humans (McGavigan et al., 2015; 
Mizushige et al., 2017). When delivered as a single agent L-Cys reduced gastric emptying and 
subsequent food intake by suppressing plasma acyl ghrelin level (McGavigan et al., 2015). 
Similarly, mRNA expression of orexigenic genes NPY and AgRP in the hypothalamus were 
suppressed in rats treated with an L-Cys-rich fish protein diet (Mizushige et al., 2017). Another 
human study reported that fish protein rich in taurine, a biosynthetic product of L-Cys was a 
more effective suppressor of appetite than either beef or chicken (Uhe, Collier & O'Dea, 1992).  
Surprisingly, on a background of a 10%P casein diet in the present study neither of the other 
two amino acids tested (L-Thr or L-Trp) either alone or in combination with L-Cys suppressed 
food intake. The lack of effect of L-Thr and L-Trp are not consistent with previous studies 
(Koehnle, Stephens & Gietzen, 2004; Meyer-Gerspach et al., 2016; Zapata et al., 2018). I 
hypothesised that the combination of three candidate amino acids would have a synergistic 
effect both on food intake and plasma FGF-21 level. While the combination successfully 
lowered plasma FGF-21 levels to that seen with L-Cys alone, no effect on food intake was 
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observed when compared to the 10%P casein control. It is possible that the drop-in plasma 
FGF-21 level precedes the drop-in food intake and that the presence of increased levels of L-
Thr and L-Trp acted to delay the suppression of food intake in response to the fall in plasma 
FGF-21 level. 
  
5.5.2 Orexigenic hormone ghrelin 
As expected, postprandial plasma ghrelin levels were suppressed in all diet groups tested (all 
10%P) regardless of whether the diets were casein or whey-based or whether the casein diet 
was supplemented with L-Cys, L-Thr or L-Trp or a combination of all three amino acids (Fig. 
5.4). These findings are consistent with previous studies (Chungchunlam et al., 2015; Veldhorst 
et al., 2009). Ghrelin is a ‘hunger hormone’ (Cummings et al., 2001). All macronutrients inhibit 
gastric ghrelin secretion and lower its plasma levels, but ingested protein is more effective than 
either carbohydrate or fat (Foster-Schubert et al., 2008). In vivo imaging has demonstrated that 
ghrelin mediates its orexigenic effects via hypothalamic NPY/AgRP neurons (Schaeffer et al., 
2013). Somewhat to our surprise, we did not observe any significant effects of whey relative 
to casein at 10%P on either fasting or postprandial plasma ghrelin levels. Furthermore, at 10%P 
when casein was supplemented with individual amino acids, we did not observe any effect of 
L-Cys, L-Thr or L-Trp on either fasting or postprandial ghrelin levels. This appears to be 
inconsistent with a recent study demonstrating that, when applied as a single test substance, L-
Cys was more effective than all other proteinogenic amino acids in suppressing food intake 
and plasma ghrelin levels in mice, rats and humans (McGavigan et al., 2015). In the study 
described in the present chapter, L-Cys was used to supplement a standardised diet rather than 
as a single agent as in the study of McGavigan et.al. In addition, the dose of L-Cys used in my 
study was substantially lower than that used in the study of McGavigan et. (McGavigan et al., 
2015). The results indicate that at 10%P level casein alone is sufficient to suppress the 
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postprandial plasma ghrelin level and that the increase in food intake on this diet arises from 
another appetite control mechanism. As discussed below, this may depend on increased plasma 
FGF-21 levels. 
 
5.5.3 PYY and Leptin 
In the context of the 10%P diet we observed that fasting plasma PYY levels were significantly 
higher in control casein-only diet compared to whey and supplementation with L-Cys, L-Thr 
or L-Trp had no additional effects (Fig. 5.5). Furthermore, no differences were observed 
between any of the groups in the postprandial state. Plasma PYY is a satiety hormone, and its 
plasma levels generally increase 15–30 min after a meal, attain their maximum after 60–90 
min, and remain elevated for several hours (Ballantyne, 2006; Batterham et al., 2003; 
Batterham et al., 2006). Postprandial PYY levels might have shown differences if blood had 
been collected at late time points between 2-4 hours consistent with its origin ileal and caecal 
endocrine cell. Recent studies on humans and rodents have reported L-Arg increases plasma 
PYY levels (Alamshah et al., 2016; Amin et al., 2018). Consistent with this, in casein has a 
higher content of L-Arg than whey (Table 6.1).  
 
It is possible that the plasma leptin level is not subject to moderation by dietary protein 
provided that significant changes in fat store do not occur the short-term nature of the study 
reported in this chapter (4 weeks per diet treatment) are likely to have reduced significant 
changes in fat stores. We did not observe significant differences in either the fasting or 
postprandial plasma leptin levels between mice in any of the diet groups.  
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5.5.4 Multiorgan energy homeostatic hormone FGF-21 
FGF-21 is  predominantly secreted by the liver (Badman et al., 2007; Inagaki et al., 2007), and 
is also secreted by fat (Hondares et al., 2011; Muise et al., 2008), skeletal muscle (Izumiya et 
al., 2008) and heart muscle (Patel et al., 2014). FGF-21 coordinates multiorgan energy balance, 
glucose metabolism and lipid metabolism (Fisher & Maratos-Flier, 2016; Kharitonenkov et al., 
2005; Woo et al., 2013). In the study described in Chapter 4, I observed that the plasma FGF-
21 level is regulated by dietary protein content such that as %P fell the plasma FGF-21 level 
increased. Solon-Biet et al. reported that low dietary protein robustly increased the plasma 
FGF-21 level (Solon-Biet et al., 2016). In humans, when %P fell from 15 to 10 plasma FGF-
21 increased 1.5 to 2 fold (Gosby et al., 2016) and in a separate study low protein diet had a 
similar effect on the plasma effect on the plasma FGF-21 level (Laeger et al., 2014). A recent 
study reported that intraperitoneal administration of FGF-21 in male mice increased protein 
intake (Larson et al., 2019), indicating that FGF-21 may be a key driver of protein appetite.     
 
In the study reported in this chapter, I observed that the fasting plasma level of FGF-21 was 
substantially increased mice receiving 10%P diets casein only compared to control whey or 
casein supplemented with L-Cys (Fig. 5.7). As noted above in recent findings indicate that 
FGF-21 promotes a specific appetite for protein (Larson et al., 2019). If this is correct, at 10%P 
either whey or supplementation of casein with L-Cys would appear to be sufficient to lower 
plasma FGF-21 and suppress the central drive for protein ingestion. In the context of limiting 
levels of L-Cys in 10%P casein, it seems possible that supplementation with L-Cys is detected 
by an amino acid sensor in the liver to lower FGF-21 production and thus plasma FGF-21 
levels. Decreased activity of orexigenic AgRP/NPY neurons and increased activity 
anorexigenic POMC neurons could have then suppressed food intake. It is possible of course 
that L-Cys may have a direct effect on hypothalamus neurons.  
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5.6 Conclusions: 
Dietary proteins, especially amino acids composition in the protein plays a significant role 
suppress appetite and regulate food intake.  In this study, I have successfully identified key 
appetite-suppressing amino acids and possible mechanism to regulate appetite. An overview 
of the key findings in this study follows below 
1. At low %P (10) food intake and the fasting plasma FGF-21 level are lower on whey 
than casein only based diets.  
2.  Supplementation of 10% casein with L-Cys to the level in 23%P whey suppressed food 
intake to the level observed with 10% and 23% whey. Two other candidate amino acids, 
L-Thr and L-Trp that are relatively enriched in whey failed to suppress food intake.  
3. At low %P, neither whey nor supplementation of casein with L-Cys suppressed fasting 
or postprandial level of the active forms of the orexigenic hormone ghrelin when 
compared with the casein only diet. Instead, all diet treatment suppressed postprandial 
levels of active ghrelin. The results are consistent with the conclusion ghrelin positively 
modulates appetite but plays no role in promoting food intake in response to a relative 
deficiency of L-Cys.  
4. PYY played no role in the control of food intake at low %P upon switching from casein 
to whey or upon supplementation of casein with L-Cys.  
5.  As %P fell from 23 to 10, the fasting plasma FGF-21 level increased with the casein 
only diet by around 2-3-fold compared to the whey diet and the casein diet supplement 
with L-Cys. The results are consistent with the hypothesis that FGF-21 promotes food 
intake at low %P and that at 10%P, whey but not casein suppresses its production. They 
also indicate that L-Cys deficiency in casein is a key factor in both the increases in 
plasma FGF-21 level and food intake. 
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6. As %P decreases in diet fasting plasma FGF-21 level increases, in control casein group 
FGF-21 increased almost 2.5-fold higher than similar %P control whey diet, and 2-fold 
in L-Cys supplemented casein diet. In this study, I have identified FGF-21 has a strong 
association with amino acid composition in diets and food intake.    
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General discussion 
 
6.1 Food intake, weight gain and obesity 
Increased food intake is one of the main drivers of developing obesity epidemic (Bleich et al., 
2008; Swinburn et al., 2009). It is generally accepted that weight gain occurs when food intake 
exceeds energy expenditure leading to progressive increases in body weight, adiposity and 
ultimately obesity (Lam & Ravussin, 2016).   As noted in the General Introduction obesity is 
a major risk factor for numerous chronic diseases, including diabetes, cardiovascular disease, 
certain cancers, osteoarthritis and chronic kidney disease (Ng et al., 2014). A better 
understanding of the control of food intake is a major challenge in designing new approaches 
to the prevention and treatment of obesity.   
 
6.2 Effect of food composition on food intake 
Food composition can influence food intake and obesity. Various studies have reported that 
certain types of food that are energy-rich but poor in protein such as French fries, sweetened 
beverages drink can markedly increase weight gain (Hall et al., 2011).  Thus, the composition 
of macronutrients in food and protein content in particular impacts total energy intake. Studies 
on humans and animals demonstrated that food intake on diets with low %P and  high  in either 
%C and/or %F is greater than diets with high %P (Gosby et al., 2011; Huang et al., 2013; 
Larsen et al., 2010; Solon-Biet et al., 2014; Sorensen et al., 2008). Previous studies also have 
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demonstrated that food intake can be determined by the ratio of P to non-P energy (Gosby et 
al., 2011; Huang et al., 2013; Solon-Biet et al., 2014; Sorensen et al., 2008).   
Protein is more effective as an appetite suppressor followed by carbohydrate and lipid 
(Barkeling, Rossner & Bjorvell, 1990; Bensaid et al., 2002; Bertenshaw, Lluch & Yeomans, 
2008; Westerterp-Plantenga et al., 2009). Consistent with this, increases in dietary protein (as 
a % of DE)  suppress appetite, reduce food intake and promote weight loss (Gosby et al., 2011; 
Gosby et al., 2014; Huang et al., 2013; Potier, Darcel & Tome, 2009; Westerterp-Plantenga et 
al., 2009). Even though protein suppresses appetite (Potier, Darcel & Tome, 2009), not all 
proteins show equal efficacy in suppressing food intake, particularly when dietary %P is low 
(Hall et al., 2003; Mizushige et al., 2017; Uhe, Collier & O'Dea, 1992; Veldhorst et al., 2009). 
Studies on humans and rodents suggest the existence of a dietary protein target (Gosby et al., 
2011; Gosby et al., 2014; Huang et al., 2013; Solon-Biet et al., 2014; Sorensen et al., 2008). 
Interestingly in an unpublished study on mice (Fig. 3.1), we previously observed differences 
in food intake with different single protein sources even though %P was identical. In particular, 
at low %P (13), we observed an increase in food intake in mice provided with casein but not 
whey, as the protein source. 
 
6.3 A key observation of food preference study 
 In the studies on C57BL/6J mice described in the thesis, I hypothesised that the amino acid 
compositions were responsible for the differences in food intake at low %P and set out to 
identify one or more amino acids that might be responsible. Bovine whey and casein are both 
considered to be high-quality proteins containing a good balance of amino acids including 
essential amino acids; I decided, therefore, to use these two widely studied proteins as a source 
of protein in a food preference study.  First, a food preference study (casein vs whey) was 
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performed to investigate whether the relative intakes of casein and whey were stable as %P 
changed. I observed two interesting outcomes 
I. stable total food intake across a broad range of %P value between 10-33;  
II. a pronounced shift in preference from casein to whey at low %P fell from 23 to 13 and 
10. 
Similar results were obtained regardless of whether %C was constant (Chapter 3) or %F was 
constant (Chapter 4) 
 
6.4 Identification of candidate amino acids 
In Chapter 3, based on the twin observation of stable food intake across a broad range of  %P 
levels (33-10) and a shift in preference from casein to whey at low %P, I hypothesized that 
food intake was stable in the context of two distinct protein sources because a relative 
deficiency of one or more amino acids in casein could be compensated by higher levels of these 
amino acids in whey. At high %P (23 and 33) casein-based diets were preferred over whey-
based diets, but as %P fell (to 13 and 10) whey-based diets were preferred, pointing to the 
existence of an optimal balance of amino acids and to prioritisation of specific amino acids that 
are concentrated in whey protein.  The preference shifts observed as %P fell presumably act to 
satisfy gut and/or central amino acid sensing mechanisms coupled to a suppression of appetite. 
Based on their intake profiles as %P fell, and food selection switched from casein to whey we 
identified three candidate amino acids (Fig. 3.6) whose intake levels were relatively stable and 
appeared to be prioritised as the food preference shifted.  These amino acids included L-Cys, 
L-Thr and L-Trp. 
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6.5 Effects of supplementing casein with candidate amino acids  
 Three amino acids L-Cys, L-Thr or L-Trp were provided as individual supplements to the 
10%P casein diet of these only L-Cys suppressed food intake to the level observed for 10%P 
whey (DE = 14 MJ/kg; see Fig. 5.3). Surprisingly, neither of the other two amino acids (L-Thr, 
L-Trp) nor the combination of all three amino acids (L-Cys, L-Thr and L-Trp) suppressed food 
intake when provided as supplements to the 10%P casein diet. Interesting control laboratory 
Chow diet has an L-Cys level intermediate between casein and whey (Table 6.1).  
 
Restriction of sulphur-containing amino acids, specifically L-Met in rodent diets, increases 
food intake and energy expenditure, and alters body composition, leading to improved 
metabolic health and a longer lifespan (Anthony, Morrison & Gettys, 2013; Jonsson, Margolies 
& Anthony, 2019). A recent study reported that supplementation of L-Met with Branch Chain 
Amino Acid supplemented diets does not supress food intake in mice (Solon-Biet et al., 2019). 
In this study I found another sulphur containing amino acid L-Cys suppresses food intake. L-
Met is an indispensable/essential amino acid. On the contrary L-Cys is a conditional essential 
amino acid. The differences observed between the actions of the two sulphur-containing amino 
acids in the studies described above and in my study, indicates that L-Cys plays a special role 
in control of food intake.  
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Table 6.1: Amino acid composition in Whey Protein Isolates and Casein and chow diet 
Amino acids contents were measured in whey and casein that used to prepare diets for study 5. In 
addition, amino acids contents in control Chow was also measured. Australian Proteome Analysis 
Facility Ltd measured amino acid contents.   
Amino acids Whey Protein Isolates 
(g/100g) 
Casein protein 
(g/100g) 
Chow diet 
(g/100g) 
L-Ala 4.7 2.9 4.1 
L-Arg 2.2 3.7 7.0 
L-Asp 10.3 6.4 9.0 
L-Cys 2.7 0.4 1.8 
L-Glu 17.2 20.6 23.6 
L-Gly 1.7 1.8 4.6 
L-His 1.7 2.7 2.7 
L-Ile 6.5 4.9 4.4 
L-Leu 10.5 8.9 7.6 
L-Lys 9.1 7.4 4.9 
L-Met 2.2 2.8 1.3 
L-Phe 3.0 4.9 4.8 
L-Pro 5.8 10.2 6.8 
L-Ser 4.8 5.5 4.9 
L-Thr 7.0 4.1 3.7 
L-Trp 1.6 0.9 1.3 
L-Tyr 2.7 5.2 2.5 
L-Val 6.2 6.5 4.9 
 
6.5.1 FGF-21 
Recent studies have reported that low protein diets increase plasma FGF-21 level (Gosby et 
al., 2016; Laeger et al., 2014; Solon-Biet et al., 2016). Furthermore, intraperitoneal 
administration of FGF-21 increased FGF-21 increased protein appetite (Larson et al., 2019). In 
the present study, I observed fasting plasma FGF-21 levels in mice on low %P L-Cys-deficient 
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casein-based diets increased substantially (Fig. 5.7 and 5.8.B). The results suggest that under 
these conditions, L-Cys suppresses plasma FGF-21 levels as well as food intake. Thus L-Cys 
appears to have modulated amino acid sensing mechanisms in the liver to negatively modulate 
FGF-21 production. FGF-21 is known to cross the blood-brain barrier (Hsuchou, Pan & Kastin, 
2007; Owen et al., 2014).  
FGF21 appear to promote health span and life expectancy (Youm et al., 2016; Zhang et al., 
2012), it is also marker of protein restriction (De Sousa-Coelho, Marrero & Haro, 2012; Laeger 
et al., 2014). Serum FGF21 levels are indeed positively correlated with health span and life 
expectancy  (Solon-Biet et al., 2016; Solon-Biet et al., 2015). In addition, protein restriction is 
associated with increased longevity (Youm et al., 2016; Zhang et al., 2012). Whether FGF21 
can be used reliably as a marker of longevity or is causally related to increased longevity is 
unknown.  
 
6.5.2 Other hormones 
As expected plasma ghrelin levels were suppressed postprandially in all diet groups tested (all 
10%P) regardless of whether the diets were casein or whey-based or whether the casein diet 
was supplemented with L-Cys, L-Thr or L-Trp or a combination of all three amino acids (Fig. 
5.4). The failure of the 10%P casein or whey diet to modify fasting and postprandial plasma 
ghrelin levels suggest that ghrelin is not involved in the L-Cys-dependent control of food intake 
and is perhaps better considered as a more general control of hunger (Cummings et al., 2001) 
rather than nutrient specific hormone. 
 
We observed that fasting plasma PYY levels during 10%P diet were significantly higher in 
control casein compared to control whey, but no other differences were observed. Recent 
studies on humans and rodents reported that L-Arg preferentially increased plasma PYY levels 
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(Alamshah et al., 2016; Amin et al., 2018). L-Arg is relatively enriched in casein when compare 
to whey (Table 6.1) providing a possible explanation for the higher fasting PYY levels in mice 
receiving casein. 
6.6 Possible mechanisms by which L-Cys might work  
Appetite regulation and induction of satiety to control food intake is a complex process. As 
discussed in Chapter 4, dietary protein induces satiety by a combination of mechanisms 
including:  
a) direct effects of amino acids on hypothalamic AgRP/NPY and POMC neurons; 
b) gut-derived hormones or neural signals; 
c) other endocrine signals including FGF-21 (Morrison & Laeger, 2015; Potier, Darcel 
& Tome, 2009).   
My results raise the interesting possibility that FGF-21 is a key hormonal regulator of L-Cys 
deficiency associated with low %P casein diets. 
 
6.6.1 FGF-21 
FGF-21 is a key metabolic hormone, coordinates multiorgan energy homeostasis, playing 
significant roles in glucose and lipid metabolism (Fisher & Maratos-Flier, 2016; Woo et al., 
2013) and acting to increase insulin sensitivity (Li et al., 2018) and promote muscle mass (Oost 
et al., 2019). It protects against atherosclerosis (Jin, Lin & Xu, 2016), mediates adaptive 
responses to stress (Kim & Lee, 2015), and modulates pancreatic progression cancer (Johnson 
et al., 2009). FGF-21 also plays a key role in the differentiation of  WAT to  BAT by enhancing 
UCP1 expression (Cuevas-Ramos, Mehta & Aguilar-Salinas, 2019; Gaich et al., 2013; 
Talukdar et al., 2016). 
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 FGF-21 is mainly expressed in the liver, and my results raise the interesting possibility that L-
Cys is a negative regulator of hepatic FGF-21 production.  
 
Several studies have reported that protein restriction or low protein diets increase serum FGF-
21 in rodents and humans (De Sousa-Coelho et al., 2013; Gosby et al., 2016; Laeger et al., 
2014; Solon-Biet et al., 2016) and a recent study has reported that IP administration of FGF-
21 stimulated protein intake in mice (Larson et al., 2019).  
 
6.6.2 Receptors: 
L-Cys might mediate its effect of appetite regulation through different receptors such as 
Metabotropic glutamate receptors (mGluR), Calcium sensing receptors (CaSR), Taste 
receptors (TIR1 and T1R3) 
 
6.6.2.1 mGluRs 
Glutamate is the principal excitatory neurotransmitter in the mammalian central nervous 
system and mediates its actions via ionotropic and metabotropic glutamate receptors 
(Hollmann et al., 1989; Pin & Duvoisin, 1995; Sugiyama, Ito & Hirono, 1987). Among these 
mGlu receptors, mGluR5 is considered to be a modulator of central reward pathways as well 
as a mediator of appetite and energy balance (Bradbury et al., 2005; Pierce et al., 1996). Sulphur 
containing amino acids, L-Cysteic acid and L-Cysteine sulphinic acid are recognised activators 
of some mGluRs, including mGluR5 (Croucher et al., 2001). Another study reported that the 
ratio of extracellular Cysteine/Cystine regulates the activity of mGluR5 (Zhu et al., 2012). It is 
possible that L-Cys maybe mediate some of the effects that I observed in my research via 
mGluR5 or other mGluRs. 
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6.6.2.2 Calcium sensing receptor (CaSR) 
The Calcium Sensing Receptor (CaSR) is another class C G-protein coupled receptor that plays 
key roles in calcium homeostasis. It senses not only Ca2+ ions but also certain L-amino acids, 
including aromatic amino acids L-Phe and L-Trp and also L-Cys (Conigrave, Quinn & Brown, 
2000). The CaSR plays a role in the control of L-Trp stimulated secretion of GLP-1 (Zapata et 
al., 2018). In another study, L-Phe enhanced the release of gut metabolite hormones and 
suppressed food intake via the CaSR (Alamshah et al., 2017). The CaSR may mediate one or 
more of the effects of L-Cys that I observed in the present studies. 
 
6.6.2.3 Leptin 
Leptin is an adipocyte generated peptide hormone, whose plasma levels rise as total body 
adiposity increases (Kwon, Kim & Kim, 2016). Leptin acts to reduce adiposity by decreasing 
food intake and increasing energy expenditure (Campfield, Smith & Burn, 1996; Zhang et al., 
1994). In the hypothalamus, leptin acts on ARC neurons to increase the production of 
anorexigenic POMC while suppressing the production of orexigenic neuropeptide Y (NPY)/ 
Agouti-related protein (AgRP). These effects act together to suppress food intake. Crystal 
structure analysis of human leptin has revealed a four-helical bundle structure, which is 
stabilised by critical intrachain disulphide (Rock et al., 1996; Zhang et al., 1997). In the study 
reported in Chapter 5, at low %P I observed a trend to an increase in the fasting plasma level 
leptin in mice constrained to whey and in mice constrained to L-Cys supplemented casein when 
compared to mice constrained to casein (Fig. 5.6). If this effect real an elevated plasma leptin 
level might contribute to the suppression of food intake in the mice on 10%P whey or casein 
supplemented with L-Cys. 
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6.6.3 FTO  
A single nucleotide polymorphism (SNP), known as AA ‘risk-allele’ in Fat mass and obesity-
related transcript (FTO) is associated with energy intake, high BMI and obesity (Frayling et 
al., 2007). FTO is highly expressed in hypothalamic nuclei and arcuate nucleus (Gerken et al., 
2007). Deficiencies of certain amino acids suppress the expression of FTO in mouse 
hypothalamic cells (N46) (Cheung et al., 2013). In particular deficiencies of L-Cys, L-Met or 
L-Gln were found to have greater effects (Cheung et al., 2013). For this reason, L-Cys rich 
diets might be used to promote FTO gene expression to suppress food intake and increase 
energy expenditure.  
 
6.7 Limitations of studies: 
• These studies were conducted only on C57BL/6J mice age from 6 months and older 
• Casein and Whey were used as the only two sources of protein tested. 
• Only high energy diet (17 MJ/kg) were used in Study 1 and 2. However, a moderate 
energy diet (14.4 MJ/kg) was used in study 3. 
•  Food intake was measured by weighing the contents of the food hoppers in each cage 
once per week. 
• In Study 3, mice were fasted overnight (12 h) for fasting blood collection. Post-prandial 
blood was only collected at one time-point 45 min after refeeding.  
• The duration of diet treatments for Studies 1 and 2 were six weeks on each %P diet 
and for Study 3 was four weeks on each %P diet. 
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6.8 Conclusions and future directions 
Control of energy intake provides one potential approach to preventing and treating overweight 
and obesity. Protein plays a key role in providing amino acids for metabolism and also 
suppresses appetite, but high protein intakes promote insulin resistance and reduce longevity.  
The food preference studies reported in this thesis provide a novel approach to answering ‘why 
different dietary proteins regulate appetite differently’ by comparing food intake of two 
different dietary proteins, casein and whey at different dietary protein levels. Even at low %P 
levels, I observed stable food intakes when mice were provided with a choice of casein and 
whey comparable to those observed at moderate to high %P casein diets, provided that 
deficiency of key amino acid, L-Cys was prevented. The results suggest that mice, and perhaps 
humans, can obtain their minimum amino acid requirements at a significantly lower total %P 
level when dietary protein provides sufficient amounts of all key amino acids, including L-Cys. 
Substantial health benefits in humans could accrue from such an approach due to lower protein 
intakes and also reduce total food intake, resulting in lower body weight, and at the same time, 
reduced protein intake, resulting in a reduced nitrogen load.
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Appendix 
Table 7.1: Fasting Serum metabolite of mice on 10%P casein, whey and casein 
supplemented with L-Cys 
 
  
Serum metabolite Diet groups Mean ± SEM P Value 
Urea (mmol/L) Whey 11.3 ± 0.4   
Casein 13.1 ± 0.4   
Casein + L-Cys 12.7 ± 0.8   
Cholesterol (mmol/L) Whey 4.2 ± 0.2 
 
Casein 3.3 ± 0.2   
Casein + L- Cys 3.6 ± 0.2   
HDL (mmol/L) Whey 2.8 ± 0.1   
Casein 2.3 ± 0.2   
Casein + L- Cys 2.5 ± 0.1   
LDL (mmol/L) Whey  0.8 ± 0.04 
 
Casein diet  0.6 ± 0.05   
Casein + L-Cys   0.6 ± 0.04   
Triglyceride 
(mmol/L)  
Whey  1.3 ± 0.1   
Casein  1.0 ± 0.1 
 
Casein + L-Cys 1.1 ± 0.1   
Albumin (g/L) Whey  33.3 ± 0.3  
Casein  30.8 ± 0.4  
Casein + L-Cys 30.9 ± 0.8  
Calcium (mmol/L) Whey  2.4 ± 0.03  
Casein  2.4 ± 0.03  
Casein + L-Cys 2.4 ± 0.02  
Phosphate (mmol/L) Whey  2.5 ± 0.1  
Casein  2.4 ± 0.2  
Casein + L-Cys 2.1 ± 0.1  
LDH (U/L) Whey  781.3 ± 178.0  
Casein  1066.3 ± 162.4  
Casein + L-Cys 896.7 ± 128.7  
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Table 7.2: Urine metabolite of mice on 10%P casein, whey and casein supplemented with 
L-Cys 
 
Metabolites in urine Diet groups Mean ± SEM P-Value 
Calcium (mmol/l) Whey  3.3 ± 0.9   
Casein  2.2 ± 0.2   
Casein + L-Cys 3.4 ± 0.3   
Creatinine (mmol/l) Whey  5.7  ± 0.3   
Casein  5.2 ± 0.2   
Casein + L-Cys 6.2 ± 0.4   
Calcium/Creatinine Ratio 
 
Whey  0.6 ± 0.1   
Casein  0.4 ± 0.0.03   
Casein + L-Cys 0.5 ± 0.05   
Phosphate (mmol/l) Whey  47.2 ± 7.9   
Casein  58.3 ± 3.1 0.011a,  
Casein + L-Cys 76.7 ± 6.1 0.000b,0.043c 
Urea (mmol/l) Whey  600.7 ± 45.1   
Casein  631.5 ± 21.6   
Casein + L-Cys 711 ± 31.2   
Glucose (mmol/l) Whey  1.7 ± 0.2   
Casein  1.4  ± 0.1  0.009d 
Casein + L-Cys 1.9 ± 0.1   
 
Notes. a Whey vs Casein, b Whey vs L-Cys + Casein, cCasein vs L-Cys + Casein, dCasein vs L-Cys + Casein   
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